Calcium channel blocker compositions formulated for transmucosal administration and methods for treating acute episodes of cardiac arrhythmias
Transmucosal administration of calcium channel blockers addresses the limitations of current treatments by providing rapid, effective, and safe management of acute cardiac arrhythmias through orally disintegrating compositions, achieving rapid therapeutic effects and enhanced bioavailability.
Patent Information
- Application Number
- PCT/CA2026/050661
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for acute cardiac arrhythmias, such as paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF), atrial flutter, supraventricular tachycardia (SVT), hypertrophic cardiomyopathy (HCM), inappropriate sinus tachycardia (1ST), and postural orthostatic tachycardia syndrome (POTS), require intravenous administration, leading to delayed therapeutic onset, systemic side effects, and the need for clinical settings, which are inadequate for rapid symptom relief.
Formulating calcium channel blockers as orally disintegrating compositions for transmucosal administration, allowing direct absorption through oral mucosal surfaces, bypassing first-pass hepatic metabolism, and providing rapid therapeutic effects comparable to intravenous delivery.
Enables patient self-administration outside clinical settings with rapid onset of action, measurable PR interval prolongation within minutes, and enhanced bioavailability, reducing the risk of systemic side effects and enabling home-based management of acute arrhythmic episodes.
Smart Images

Figure CA2026050661_12112026_PF_FP_ABST
Abstract
Description
CALCIUM CHANNEL BLOCKER COMPOSITIONS FORMULATED FOR TRANSMUCOSAL ADMINISTRATION AND METHODS FOR TREATING ACUTE EPISODES OF CARDIAC ARRHYTHMIASCROSS REFERENCE TO RELATED APPLICATION
[0001] The present application claims the benefit of U.S. Provisional Patent Application No.63 / 800,646, filed May 6, 2025, which is incorporated herein by reference in its entirety.TECHNICAL FIELD
[0002] This application generally relates to the field of fast-acting compositions and methods for treating acute episodes of cardiac arrhythmias. More particularly, this application relates to compositions and methods for administration of a composition containing a calcium channel blocker for treatment of acute episodes of cardiac arrhythmias in a rapid and non-invasive manner.BACKGROUND
[0003] Cardiac arrhythmias, including paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF), atrial flutter, supraventricular tachycardia (SVT), hypertrophic cardiomyopathy (HCM), inappropriate sinus tachycardia (1ST), and postural orthostatic tachycardia syndrome (POTS), represent a significant clinical challenge affecting millions of patients worldwide. These conditions are characterized by abnormal electrical activity in the heart resulting in rapid or irregular heart rates, which can lead to hemodynamic instability, palpitations, chest pain, syncope, and increased long-term risk of stroke, heart failure, or sudden cardiac death. Acute episodes of these arrhythmias require prompt intervention to restore normal cardiac rhythm and prevent potentially life-threatening complications.
[0004] Currently, the management of acute arrhythmic episodes relies predominantly on interventions that must be performed in a controlled clinical environment, creating a significant treatment gap. Pharmacological conversion typically requires intravenous (IV) administration of antiarrhythmic agents such as adenosine, beta-blockers, or calcium channel blockers. This necessity for IV access and continuous cardiac monitoring mandates that patients seek care in an emergency department or hospital setting. The resulting delay between symptom onset and professional medical intervention, which may range from thirty minutes to several hours depending on patient location and emergency department capacity, prolongs patient distress,increases healthcare costs, and elevates the risk of tachycardia-induced complications including cardiomyopathy from prolonged episodes.
[0005] Prior attempts to develop non-intravenous rapid-acting antiarrhythmic formulations have been unsuccessful in achieving the required speed of onset. Conventional oral tablets containing calcium channel blockers such as verapamil are subject to extensive first-pass hepatic metabolism, resulting in low bioavailability (approximately 14-22% for verapamil) and delayed time to maximum plasma concentration (Tmax), typically one to two hours postadministration. Even sublingual administration of crushed conventional tablets has proven inadequate: Fort et al. ( Br J Clin Pharmacol 1992 Jun;33(6):623-7) reported that sublingual administration of a crushed verapamil 40 mg tablet produced a T max of approximately one hour, with peak pharmacodynamic effect (PR interval prolongation) occurring at 30 to 90 minutes post-administration. This timeframe remains unsuitable for acute arrhythmia management, where therapeutic effect is needed within minutes to prevent complications.
[0006] Furthermore, existing treatments for acute arrhythmic episodes are associated with significant drawbacks that limit their clinical utility. Intravenous antiarrhythmic agents can cause severe systemic side effects including hypotension, bradycardia, bronchospasm, and in rare cases, paradoxical arrhythmias. Oral formulations of calcium channel blockers and other antiarrhythmic agents that are swallowed undergo first-pass hepatic metabolism, resulting in delayed onset of action (typically 1-2 hours to reach therapeutic plasma concentrations) and reduced bioavailability, rendering them unsuitable for acute episode management where rapid symptom relief is essential. In cases where pharmacological intervention proves ineffective or is contraindicated, synchronized electrical cardioversion becomes necessary, which remains an invasive procedure requiring sedation and specialized equipment available only in clinical settings. Non-pharmacological approaches such as vagal maneuvers have variable success rates and are frequently insufficient to terminate episodes.
[0007] Accordingly, there remains a significant unmet clinical need for improved approaches to managing acute arrhythmic episodes that address the limitations of current treatment modalities, including the requirement for clinical settings, delayed therapeutic onset, systemic side effects, and the need for continuous medical monitoring.SUMMARY
[0008] This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identifykey aspects or essential aspects of the claimed subject matter. Moreover, this Summary is not intended to limit the scope of the claimed subject matter.
[0009] The present disclosure addresses the unmet clinical need identified above by providing compositions, kits, and methods for the treatment of acute episodes of cardiac arrhythmias. In one aspect, the present disclosure relates to a composition formulated for transmucosal administration through oral mucosal surfaces for use in treatment of an acute episode of cardiac arrhythmia. The composition comprises a therapeutically effective amount of a calcium channel blocker, or a pharmaceutically acceptable salt, enantiomer, racemic mixture, active metabolite, or combination thereof, and at least one pharmaceutically acceptable excipient, diluent, carrier, or combination thereof. The composition is formulated as an orally disintegrating dosage form for placement under or over the tongue for transmucosal administration, and the transmucosal administration produces a measurable prolongation of the PR interval relative to baseline within 15 minutes of administration.
[0010] In another aspect, the present disclosure relates to a kit or commercial package comprising: (a) a first dose of the composition described above, wherein the calcium channel blocker, or a pharmaceutically acceptable salt, enantiomer, racemic mixture, active metabolite, or combination thereof, is a first calcium channel blocker, or a pharmaceutically acceptable salt, enantiomer, racemic mixture, active metabolite, or combination thereof; and (b) one or more doses of an oral composition that is swallowed, the oral composition comprising a second calcium channel blocker, or a pharmaceutically acceptable salt, enantiomer, racemic mixture, active metabolite, or combination thereof. The kit provides both immediate symptom relief through the transmucosal composition and sustained therapeutic effect through the oral swallowed composition.
[0011] In yet another aspect, the present disclosure relates to a method for treatment of an acute episode of cardiac arrhythmia. The method comprises placing a composition on or under the tongue of the subject and maintaining it in contact with oral mucosal surfaces for a period sufficient for transmucosal absorption of a therapeutically effective amount of a calcium channel blocker, or a pharmaceutically acceptable salt, enantiomer, racemic mixture, active metabolite, or combination thereof, directly into the systemic circulation. In some embodiments, the period sufficient for transmucosal absorption is from about 5 minutes to about 15 minutes, such as about 10 minutes. In some embodiments, the transmucosal absorption produces a measurable prolongation of the PR interval relative to baseline within 15 minutes of administration, within 10 minutes of administration, within 5 minutes of administration, or within 2 minutes of administration. The composition comprises the calcium channel blocker and at least one pharmaceutically acceptable excipient or carrier. The method enables patient self-administration outside clinical settings while achieving rapid onset of action comparable to intravenous administration.
[0012] In some embodiments, the cardiac arrhythmia is selected from the group consisting of paroxysmal supraventricular tachycardia (PSVT), supraventricular tachycardia (SVT), hypertrophic cardiomyopathy (HCM), inappropriate sinus tachycardia (1ST), atrial fibrillation (AFib), and postural orthostatic tachycardia syndrome (POTS). In some embodiments, the cardiac arrhythmia is PSVT with rapid ventricular response (RVR).
[0013] In some embodiments, the calcium channel blocker is selected from the group consisting of verapamil, gallopamil, devapamil, amlodipine, diltiazem, nifedipine, nimodipine, isradipine, lacidipine, etripamil, benidipine, felodipine, nicardipine, lercanidipine, and pharmaceutically acceptable salts, enantiomers, racemic mixtures, active metabolites, and combinations thereof. In preferred embodiments, the calcium channel blocker is verapamil or a pharmaceutically acceptable salt thereof.
[0014] In some embodiments, the composition is in the form of an orally disintegrating tablet, orally disintegrating film, sublingual spray, or other dosage form suitable for transmucosal administration. Preferably, the composition is in the form of an orally disintegrating tablet or orally disintegrating film.
[0015] In some embodiments, the composition exhibits a pharmacokinetic profile characterized by a time to maximum plasma concentration (T max) of less than or equal to about 10 minutes, or less than or equal to about 5 minutes. In some embodiments, the composition exhibits a maximum plasma concentration (Cmax) of at least 200 ng / mL, or at least 500 ng / mL, after administration of a single dose. In some embodiments, the composition exhibits a rapid clearance profile characterized by a plasma concentration at 30 minutes post-administration that is less than about 30% of the maximum plasma concentration (Cmax).
[0016] In yet a further aspect, the present disclosure relates to a method for treatment of an acute episode of cardiac arrhythmia in which the transmucosal administration produces a norverapamil-to-verapamil systemic exposure ratio of less than 1.0, as measured by the ratio of norverapamil AUC to verapamil AUC. This low metabolite ratio indicates predominantly transmucosal absorption rather than gastrointestinal absorption, where first-pass hepatic metabolism would generate higher levels of the norverapamil metabolite. In some embodiments, the norverapamil-to-verapamil ratio is less than 0.75, less than 0.5, or from about 0.2 to about 0.4 (comparable to that observed following intravenous administration).
[0017] In some embodiments, the transmucosal administration produces a measurable increase in heart rate of a healthy subject (i.e., not experiencing an acute episode of cardiac arrhythmia) relative to baseline within 5 minutes of administration. Without being bound by theory, this heart rate increase in healthy subjects is believed to result from reflex tachycardia, a compensatory physiological response to verapamil’s vasodilatory effect on peripheral blood vessels, and serves as a pharmacodynamic biomarker confirming rapid systemic drug delivery via transmucosal absorption. This effect in healthy subjects is distinct from the therapeutic effect observed in subjects experiencing an acute episode of cardiac arrhythmia such as PSVT, where verapamil’s action at the AV node interrupts the re-entrant circuit, resulting in termination of the arrhythmic episode and reduction in heart rate. In some embodiments, the measurable increase in heart rate in a healthy subject is at least 8% above baseline within 5 minutes of administration. In some embodiments, the measurable prolongation of the PR interval comprises an increase of at least 5% or at least 8% relative to baseline, and may reach a maximum at approximately 10 minutes post-administration.
[0018] In another aspect, the present disclosure relates to a composition for treatment of an acute episode of cardiac arrhythmia that exhibits enhanced bioavailability. The composition, when maintained in contact with oral mucosal surfaces for transmucosal absorption, exhibits an absolute bioavailability of at least 25%, at least 30%, or at least 40%. In some embodiments, the absolute bioavailability is at least two-fold greater than the bioavailability of an equivalent dose of verapamil administered as a conventional oral swallowed tablet.
[0019] In another aspect, the present disclosure relates to a composition for use in patient self-administration for treatment of an acute episode of cardiac arrhythmia outside a clinical setting. The composition comprises a therapeutically effective amount of verapamil or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein the composition is formulated as an orally disintegrating dosage form for placement under or over the tongue for transmucosal administration. In some embodiments, the subject self-administers the composition upon onset of symptoms of the acute episode of cardiac arrhythmia. In some embodiments, during the period sufficient for transmucosal absorption, the subject refrains from swallowing to maximize transmucosal absorption and minimize gastrointestinal uptake.
[0020] In a further aspect, the present disclosure relates to a composition comprising verapamil or a pharmaceutically acceptable salt thereof in an amount of from about 20 mg to about 40 mg that exhibits dose-proportional pharmacokinetics across the dose range, as characterized by a power model exponent for AUC of from about 0.8 to about 1.2.
[0021] All features of embodiments which are described in this disclosure and are not mutually exclusive can be combined with one another. Elements of one embodiment can be utilized in the other embodiments without further mention. Other aspects, features, advantages, and benefits of the compositions, kits, and methods of the present disclosure will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments in conjunction with the accompanying Figures.BRIEF DESCRIPTION OF THE DRAWINGS
[0022] For a better understanding of the various embodiments described herein, and to show more clearly how these various embodiments may be carried into effect, reference will be made, by way of example, to the accompanying drawings which show at least one example embodiment, and which are now described. The drawings are not intended to limit the scope of the teachings described herein. In the drawings:
[0023] FIG. 1 is a non-limiting graph reporting the overall effect on heart rate of a composition containing verapamil formulated for transmucosal administration and of reference product verapamil formulated for oral administration, in accordance with an embodiment of the present disclosure.
[0024] FIG. 2 is a non-limiting graph reporting the overall effect on heart rate of a composition containing verapamil formulated for transmucosal administration and of reference product verapamil formulated for intravenous administration, in accordance with an embodiment of the present disclosure.
[0025] FIG. 3 is a non-limiting graph reporting the overall effect on heart rate of a monotherapy with a composition containing verapamil formulated for transmucosal administration compared to a combination therapy with a composition containing verapamil formulated for transmucosal administration and a composition containing verapamil formulated for oral administration that is swallowed, in accordance with embodiments of the present disclosure.
[0026] FIG. 4 is a non-limiting representative electrocardiogram (ECG) trace of a patient illustrating a PR interval (i.e., the time from the start of the P wave (atrial depolarization) to the beginning of the QRS complex (ventricular depolarization), representing conduction through the AV node) prolongation relative to baseline following the sublingual administration of a composition in accordance with an embodiment of the present disclosure.
[0027] FIG. 5 shows heart rate increasing above baseline (to ~109%) of the patient in FIG. 4, which is consistent with a reflex tachycardia response to verapamil's vasodilatory effect. Ameasurable cardiovascular PD effect is observed within 2 minutes demonstrating rapid systemic drug delivery via transmucosal absorption.
[0028] In the drawings, some embodiments are illustrated by way of example. It is to be expressly understood that the description and drawings are only for the purpose of illustrating certain embodiments and are an aid for understanding. They are not intended to be a definition of the limits of the disclosure.DETAILED DESCRIPTION
[0029] The present technology is explained in greater detail below. This description is not intended to be a detailed catalog of all the different ways in which the technology may be implemented, or all the features that may be added to the instant technology. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art considering the instant disclosure which variations and additions do not depart from the present technology. Hence, the following description is intended to illustrate some embodiments of the technology, and not to exhaustively specify all permutations, combinations, and variations thereof. As such, this detailed description of various embodiments should not be construed to limit the scope or breadth of the appended claims.Definitions
[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art to which the present disclosure pertains. As used herein, and unless stated otherwise or required otherwise by context, each of the following terms shall have the definition set forth below.
[0031] As used herein, "sequentially administering" means that administration is separated in time, e.g., separated by a predetermined interval (e.g., minutes, or hours).
[0032] As used herein, 'transmucosal administration' refers to delivery of the active agent through the oral mucosal membranes directly into the systemic circulation, as distinguished from conventional oral administration in which the dosage form is swallowed and the active agent is absorbed through the gastrointestinal tract. Transmucosal administration includes, but is not limited to, sublingual administration (placement under the tongue), supralingual administration (placement over the tongue), and buccal administration (placement against the cheek).
[0033] As used herein, the term “predominantly transmucosal absorption” refers to absorption of the active ingredient through the oral mucosal surfaces directly into the systemic circulation to a degree that is objectively distinguishable from conventional gastrointestinal absorption with first-pass hepatic metabolism. For calcium channel blockers that undergo hepatic first-pass metabolism to form an active metabolite (such as verapamil, which is metabolized to norverapamil by CYP3A4), predominantly transmucosal absorption may be characterized by a metabolite-to-parent systemic exposure ratio (measured as the ratio of AUC(inf) of the metabolite to AUC(inf) of the parent compound, determined by standard noncompartmental analysis) that is less than 1.0, preferably less than 0.75, more preferably less than 0.5, and most preferably approaching the ratio observed following intravenous administration of the same active ingredient (for example, approximately 0.26 to 0.32 for verapamil). A metabolite-to-parent AUC ratio at or above 1.0 indicates that the majority of the absorbed active ingredient underwent hepatic first-pass metabolism prior to reaching the systemic circulation, which is characteristic of gastrointestinal absorption following swallowing rather than transmucosal absorption through the oral mucosa.
[0034] As used herein, the term “period sufficient for transmucosal absorption” refers to a duration of contact between the composition and the oral mucosal surfaces that is adequate to achieve direct absorption of a therapeutically effective amount of the active ingredient into the systemic circulation through the oral mucosa, bypassing first-pass hepatic metabolism. The sufficiency of the period may be confirmed by one or more objective measures including: (i) a metabolite-to-parent systemic exposure ratio indicative of predominantly transmucosal absorption (e.g., less than 1.0 for calcium channel blockers metabolized hepatically); (ii) a measurable prolongation of the PR interval relative to baseline; (iii) a time to maximum plasma concentration (Tmax) of less than or equal to about 10 minutes; or(iv) an absolute bioavailability exceeding that of the same active ingredient administered as a conventional oral swallowed tablet. The period sufficient for transmucosal absorption may vary depending on the specific composition, dosage form, active ingredient, dose, and individual subject factors.
[0035] “Concomitant” and “concomitantly” as used herein refer to the administration of a dose to a patient either subsequently, simultaneously, or consequently within a time period during which the effects of the first administered dose is still operative in the patient.
[0036] “Providing” means giving, administering, selling, distributing, transferring (for profit or not), manufacturing, compounding, dispensing, or a combination thereof.
[0037] “Dosage amount” means an amount of a drug suitable to be taken during a fixed period, usually during one day (i.e., daily).
[0038] “Dosage amount adapted for oral (or mucosal) administration” means a dosage amount that is of an amount deemed suitable for the particular patient under the conditions specified and formulated fortransmucosal absorption of the calcium channel blocker. As used herein and in the claims, this dosage amount can be determined by following the recommendations of the drug manufacturer's Prescribing Information as approved by a regulatory authority, such as the US Food and Drug Administration.
[0039] “Dosing regimen” means a schedule of doses of a drug or medicine, including the dosing interval and dose at which a drug is to be administered or taken. For example, a dosing regimen includes the dose of a drug taken at a first time by a patient and the interval (time or symptomatic) and dosage amounts at which any subsequent doses of the drug are taken by the patient. Each dose may be of the same or a different dosage amount.
[0040] A “dose” means the measured quantity of a drug to be taken at one time by a patient.
[0041] A “patient” means a mammal, such as a human or a dog, in need of medical treatment.
[0042] As used herein, the term “Cmax” refers to the maximum observed concentration, occurring at Tmax.
[0043] As used herein, the term “Tmax” refers to the time of maximum observed concentration corresponding to Cmax.
[0044] As used herein, the term “measurable prolongation of the PR interval” refers to an increase in PR interval that is detectable by standard electrocardiographic measurement, typically representing an increase of at least 1% above the baseline PR interval value, more typically at least 2%, at least 4%, at least 5%, at least 6%, at least 8%, at least 10%, or at least 12% above baseline.
[0045] As used herein, the term AUCt refers to “Area Under the Curve” from the time of dosing up to the last measurable concentration (other common abbreviations: AUCiast or AUC0-t), generally calculated by trapezoidal method. AUC0-2 is the area under the curve from dosing to two hours after dosing.
[0046] In general, the term “average maximum calcium channel blocker plasma concentration Cmax” within the present disclosure is defined as geometric mean maximum plasma concentration of the calcium channel blocker calculated from individual maximum plasma concentrations as determined from plasma concentration time profiles.
[0047] The term "tachycardia" as used herein refers to a resting heart rate that is elevated relative to a normal state.
[0048] The term "cardiac arrhythmia" as used herein refers to a condition characterized by abnormal heart rhythms that may be irregular, excessively fast, too slow, or conducted through an abnormal electrical pathway in the heart. Cardiac arrhythmias include supraventricular tachycardia (SVT), a rapid heart rhythm originating above the ventricles, including paroxysmal supraventricular tachycardia (PSVT), which presents as a sudden onset of fast and regular heartbeats. Additionally, cardiac arrhythmias include ventricular tachycardia, which is characterized by a rapid heartbeat originating in the lower chambers of the heart. Other conditions associated with abnormal heart rhythms include hypertrophic cardiomyopathy (HCM), a genetic disorder characterized by thickened heart muscle that can lead to arrhythmias and tachycardia. Inappropriate sinus tachycardia (1ST) is a condition in which the resting heart rate is abnormally high due to excessive sinus node activity without an identifiable cause. Postural orthostatic tachycardia syndrome (POTS) is a disorder characterized by an excessive increase in heart rate upon standing, often accompanied by symptoms such as dizziness and fatigue.
[0049] As used herein, the term “PR interval” refers to the time from the start of the P wave (atrial depolarization) to the beginning of the QRS complex (ventricular depolarization) as measured on an electrocardiogram (ECG), representing the time for electrical conduction through the atrioventricular (AV) node. Prolongation of the PR interval indicates slowing of AV nodal conduction, which is a pharmacodynamic marker of calcium channel blocker activity at the AV node.
[0050] The term "excipient" is used herein to describe any ingredient other than an active compound(s) described herein. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, or waters of hydration. Some excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearicacid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol. Additional excipients may include, without limitation, polysorbate, propylene glycol, hydroxypropyl |3-cyclodextrin, triethylcitrate, benzalkonium chloride, and / V-dodecyl-p-D-maltoside.
[0051] As used herein, the terms “pharmaceutically acceptable” or “pharmacologically acceptable” refer to a substance that is acceptable for administration to the mammal being treated.
[0052] As used herein, a "pharmaceutically acceptable salt" or "pharmaceutically acceptable acid addition salt" of a basic pharmaceutically active compound is derived from the treatment of the compound with an organic acid or an inorganic acid.
[0053] As used herein, a "pharmaceutically acceptable carrier" refers to a vehicle capable of suspending or dissolving the active compound, and having the properties of being suitable for inclusion in a composition to be administered to a patient. Moreover, a pharmaceutically acceptable carrier may include a pharmaceutically acceptable additive, such as a preservative, antioxidant, fragrance, emulsifier, dye, or excipient known or used in the field of drug formulation and that is suitable for inclusion in a composition to be administered to a patient.
[0054] The term "pharmaceutically acceptable formulation" As used herein, refers to a composition including a pharmaceutically acceptable carrier and at least one active compound, i.e., a calcium channel blocker.
[0055] As used herein, the term “active ingredient” refers to a calcium channel blocker active ingredient, specifically a calcium channel blocker, or a pharmaceutically acceptable salt thereof, an active metabolite thereof, or any combination thereof, that provides the therapeutic effect of the composition. It is understood that when an “active metabolite” is administered as the active ingredient, the metabolite itself exerts the therapeutic effect. The term “active ingredient” as used throughout this disclosure encompasses: (i) any calcium channel blocker in its free base or free acid form; (ii) any pharmaceutically acceptable salt of a calcium channel blocker (such as hydrochloride, sulfate, phosphate, acetate, citrate, fumarate, maleate, succinate, tartrate, or other pharmaceutically acceptable salts); and (iii) any active metabolite of a calcium channel blocker that retains calcium channel blocking activity (such as norverapamil, which is an active metabolite of verapamil). For the avoidance of doubt, each use of the term “active ingredient” throughout this specification refers to a calcium channel blocker active ingredient as defined herein. While the examples herein employ verapamil hydrochloride as a representative calcium channel blocker, the skilled person will appreciate that the compositions, methods, and uses described herein are broadly applicable to any calcium channel blocker, salt thereof, or activemetabolite thereof, that achieves the rapid transmucosal absorption characteristics described herein.
[0056] The selection of a particular calcium channel blocker, salt, or active metabolite for use in the compositions described herein is guided by factors including: (a) calcium channel blocking activity, particularly L-type calcium channel blocking activity relevant to cardiac conduction; (b) physicochemical properties suitable for transmucosal absorption, including water solubility, lipophilicity, and molecular weight; (c) stability in oral mucosal formulations; and (d) pharmacokinetic profile suitable for acute treatment, including rapid absorption and appropriate clearance. Calcium channel blockers suitable for use in the present compositions include, but are not limited to, verapamil, diltiazem, gallopamil, devapamil, and pharmaceutically acceptable salts and active metabolites thereof. In preferred embodiments, the calcium channel blocker is verapamil or a pharmaceutically acceptable salt thereof, such as verapamil hydrochloride.
[0057] As used herein, the term "therapeutically effective amount" refers to an amount of an active compound that is effective in the diagnosis, cure, mitigation, or prevention of disease in a human or other animals, or an amount that otherwise affects the structure or any function of the body of a human or other animals. In some embodiments, the active compound may be present in an amount that is effective to diagnose, cure, mitigate, or prevent cardiac arrhythmia, such as PSVT, SVT, HCM, 1ST, Afib, and POTS.
[0058] As used herein, the term “orally disintegrating dosage form” refers to a solid dosage form that dissolves or disintegrates rapidly in the oral cavity upon contact with saliva, without the need for water or chewing, and includes orally disintegrating tablets (ODTs) and orally disintegrating films (ODFs). As used herein, the term “orally disintegrating tablet” or “ODT” refers to a solid tablet dosage form that disintegrates rapidly upon contact with saliva. As used herein, the term “orally disintegrating film” or “ODF” refers to a thin, flexible film dosage form that dissolves or disintegrates rapidly upon contact with saliva.Treatment of Acute Episodes of Cardiac Arrhythmia
[0059] The present inventors have developed a fast-acting therapeutic approach for treating cardiovascular disorders in a subject in need thereof, particularly acute episodes of cardiac arrhythmias. This approach addresses the critical unmet need identified above by providing one or more of the following technical advantages: (a) the treatment can be self-administered by the patient without medical supervision, eliminating the need for emergency department visits in many cases; (b) the treatment enables home-based or ambulatory management of acute arrhythmic episodes; (c) the treatment achieves rapid onset of therapeutic effect comparable tointravenous administration; (d) the treatment provides rapid absorption followed by appropriate clearance, affording acute symptom control while limiting prolonged cardiovascular effects or unwanted pharmacodynamic activity; and (e) the treatment offers a favorable safety profile suitable for patient self-administration.
[0060] In some embodiments, the method for patient self-administration of acute treatment for an episode of cardiac arrhythmia outside a clinical setting comprises: (a) providing a composition comprising a therapeutically effective amount of verapamil or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, formulated as an orally disintegrating dosage form; (b) placing the composition under the tongue without medical supervision; and (c) maintaining the composition in contact with oral mucosal surfaces for a period sufficient for transmucosal absorption directly into the systemic circulation. In preferred embodiments, the transmucosal absorption produces a measurable prolongation of the PR interval relative to baseline within 15 minutes of administration, more preferably within 10 minutes, even more preferably within 5 minutes, and most preferably within 2 minutes.
[0061] In some embodiments, the fast-acting approach comprises transmucosal administration of a composition for treating a cardiovascular disorder, such as a cardiac arrhythmia, particularly acute episodes thereof. Transmucosal administration provides direct absorption of the active ingredient into the systemic circulation, bypassing first-pass hepatic metabolism, resulting in faster time to maximum plasma concentration (Tmax), higher peak plasma concentration (Cmax) relative to oral swallowed administration at equivalent doses, and more predictable bioavailability.
[0062] Transmucosal administration enables permeation of the active ingredient directly into the bloodstream and subsequently into target cells (e.g., cardiomyocytes) within minutes. The oral mucosa presents a highly vascularized epithelial surface that provides an efficient absorption pathway. Within the oral cavity, mucosal surfaces that may be utilized include: (i) sublingual surfaces, e.g., the mucosal membranes lining the floor of the mouth, which provide particularly rapid absorption due to the thin epithelium and rich blood supply; (ii) buccal surfaces, e.g., the mucosal membranes lining the cheeks; (iii) lingual surfaces, e.g., the surface membranes of the tongue; (iv) palatal surfaces, e.g., the membranes lining the roof of the mouth; (v) pharyngeal surfaces, e.g., the membranes of the pharynx; (vi) gingival mucosa, e.g., the gums; and (vii) gingival sulcus, e.g., the cavity formed between the teeth and gums.
[0063] In some embodiments, the composition is placed under or over the tongue for transmucosal administration. Placement under the tongue (sublingual administration) positions the composition in contact with the highly vascularized sublingual mucosa. Placement over thetongue (supralingual administration) positions the composition on the dorsal surface of the tongue in contact with the lingual mucosa. Both routes provide effective transmucosal absorption directly into the systemic circulation, bypassing first-pass hepatic metabolism. In preferred embodiments, the composition is placed under the tongue, which may provide particularly rapid absorption due to the thin epithelium and rich blood supply of the sublingual mucosa.
[0064] Without being bound by any particular theory, it is believed that transmucosal administration through oral mucosal surfaces of a composition comprising an active ingredient as defined herein has not previously been successfully exploited for treating acute episodes of cardiac arrhythmias requiring rapid therapeutic intervention. The prior art has generally employed oral swallowed delivery of calcium channel blockers, which causes the active agent to pass through the gastrointestinal tract with subsequent first-pass hepatic metabolism. This metabolic processing significantly delays the entry of the active agent into the systemic circulation and reduces bioavailability, thereby delaying the onset of therapeutic effect on cardiac tissue. While sublingual administration of a crushed verapamil 40 mg tablet (Fort, et al., (1992), Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.. British Journal of Clinical Pharmacology, 33: 623-627) has been reported to produce greater plasma verapamil concentration and greater percentage increase in PR interval (a measure of atrioventricular conduction) compared with oral swallowed dosing, the crushed tablet formulation generated a Tmax of approximately one hour and the greater increase in PR interval occurred at approximately 30 to 90 minutes post-administration. This time frame is unsuitable for effective acute arrhythmia management, where therapeutic effect is needed within minutes. The present inventors have discovered that the combination of: (i) specifically formulated orally disintegrating compositions for transmucosal administration as described herein; and (ii) the method of maintaining the composition in contact with oral mucosal surfaces for a period sufficient for transmucosal absorption, achieves a time to maximum plasma concentration (Tmax) of less than or equal to about 10 minutes, preferably less than or equal to about 5 minutes, and produces measurable PR interval prolongation (e.g., at least 5% increase) within 2 minutes of administration, results that are substantially faster than prior art swallowable or crushed formulations and that enable patient self-administration for treatment of an acute episode of cardiac arrhythmias outside a clinical setting.
[0065] The method described herein requires the deliberate act of placing the composition on or under the tongue and maintaining it in contact with oral mucosal surfaces for a period sufficient for transmucosal absorption. In preferred embodiments, the period sufficient for transmucosal absorption is from about 4 minutes to about 15 minutes. This is fundamentallydistinct from orally disintegrating tablets designed for convenience of swallowing, where the active agent is subsequently absorbed through the gastrointestinal tract. The present inventors have discovered that when compositions as described herein are administered by the transmucosal method and maintained in contact with oral mucosal surfaces for the period described herein, the resulting pharmacodynamic effect (measurable PR interval prolongation within 10 minutes, and preferably within 2 minutes) is achieved more rapidly than with prior art swallowable or crushed formulations. This rapid onset demonstrates the technical contribution of the method of administration itself.
[0066] In some embodiments, during the period sufficient for transmucosal absorption, the subject refrains from swallowing to maximize transmucosal absorption and minimize gastrointestinal uptake. By consciously avoiding swallowing during the period of mucosal contact, the subject ensures that the active ingredient remains in contact with the oral mucosal surfaces for the intended duration, thereby maximizing the proportion of the dose absorbed transmucosally rather than being subjected to first-pass hepatic metabolism. In some embodiments, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% of the calcium channel blocker, such as verapamil, is swallowed.
[0067] In some embodiments, the cardiac arrhythmias may include any one of a condition selected from paroxysmal supraventricular tachycardia (PSVT), supraventricular tachycardia (SVT), hypertrophic cardiomyopathy (HCM), inappropriate sinus tachycardia (1ST), atrial fibrillation (AFib), and postural orthostatic tachycardia syndrome (POTS). In particular, acute episodes of any one thereof.
[0068] In some embodiments, the cardiac arrhythmia is characterized by an abnormally rapid heart rate, and the treatment achieves a reduction in heart rate or termination of the arrhythmic episode. In some embodiments, the subject experiences one or more symptoms of the acute arrhythmic episode prior to administration, including but not limited to palpitations, rapid or irregular heartbeat, chest discomfort or pain, light-headedness, dizziness, shortness of breath, or syncope. Following administration of the composition according to the method described herein, the subject may experience reduction or resolution of these symptoms.
[0069] In some embodiments, the cardiac arrhythmia is PSVT. For example, PSVT with rapid ventricular response (RVR).
[0070] In some embodiments, the subject includes any subject, generally a mammal (e.g., human, canine, feline, equine, bovine, etc.), in which treatment for the herein describedcardiovascular disorders is desired. For example, the subject can be a human. For example, a child or an adult. For example, a man or a woman.
[0071] In some embodiments, the subject is a human patient who has been diagnosed with or is experiencing symptoms of a cardiac arrhythmia. In some embodiments, the subject is an adult human. In some embodiments, the subject is a pediatric patient. The dosage may be adjusted based on subject weight, age, and clinical condition.
[0072] In some embodiments, transmucosal absorption of the active ingredient is characterized by a metabolite-to-parent systemic exposure ratio that is objectively distinguishable from gastrointestinal absorption with first-pass hepatic metabolism. For embodiments in which the active ingredient is verapamil, transmucosal absorption may be confirmed by a norverapamil-to-verapamil AUC ratio of less than 1.0, less than 0.75, less than 0.5, or approaching the ratio observed following intravenous administration (approximately 0.26 to 0.32). When the method described herein is properly followed (i.e., the composition is maintained in contact with oral mucosal surfaces and the subject refrains from swallowing during the period sufficient for transmucosal absorption), the resulting metabolite-to-parent ratio reflects predominantly transmucosal absorption bypassing first-pass hepatic metabolism, as demonstrated in Example 7 herein.
[0073] In some embodiments, the transmucosal absorption results in an absolute bioavailability of the active ingredient that exceeds the bioavailability achieved by conventional oral swallowed administration of the same active ingredient. For verapamil, conventional oral swallowed administration is reported to produce an absolute bioavailability of approximately 14% to 22%. In some embodiments, the compositions and methods described herein achieve an absolute bioavailability of at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% when administered according to the transmucosal method described herein. In some embodiments, the absolute bioavailability is at least two-fold greater than the bioavailability achieved by an equivalent dose administered as a conventional oral swallowed tablet.
[0074] In some embodiments, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of the dose of the active ingredient is absorbed through the oral mucosa directly into the systemic circulation, bypassing first-pass hepatic metabolism. The fraction of the dose absorbed transmucosally may be estimated by pharmacokinetic modeling, by deconvolution analysis, or by comparison of metabolite-to-parent ratios with intravenous reference data, as described in Example 7 herein.Composition, Dosage Forms, and Active Ingredient
[0075] In one non-limiting practical implementation, the composition includes an active ingredient which comprises a calcium channel blocker, salt, active metabolite, or any combinations thereof. The composition is formulated as an orally disintegrating dosage form for use in treatment of an acute episode of cardiac arrhythmia in a subject.
[0076] When administered by placing under or over the tongue and maintaining in contact with oral mucosal surfaces for transmucosal absorption, the composition achieves a Tmax of less than or equal to about 10 minutes. In preferred embodiments, the Tmax is less than or equal to about 5 minutes. In particularly preferred embodiments, the Tmax is less than about 5 minutes, as demonstrated in the experimental results where peak plasma concentration was observed at the first sampling timepoint (5 minutes post-administration), indicating the actual Tmax may be shorter.
[0077] In some embodiments, the composition comprises an amount of the active ingredient sufficient to achieve a therapeutically effective physiological response, such as termination of an acute arrhythmic episode or reduction in heart rate, within a therapeutically useful timeframe. More particularly, the therapeutically effective amount is selected to achieve the desired effect within a rapid timeframe suitable for acute treatment (i.e., with fast onset of action, typically within 2 to 10 minutes of administration, and appropriate systemic clearance to afford acute symptomatic treatment while limiting prolonged side effects). The selection of an appropriate therapeutically effective amount considers factors including the specific calcium channel blocker employed, the target arrhythmia indication, patient weight and condition, and the desired pharmacokinetic profile.
[0078] Formulating calcium channel blockers for effective transmucosal administration through oral mucosal surfaces presents several technical challenges that the present compositions address. These challenges include: (a) water solubility, which can limit the ability of the active ingredient to dissolve rapidly in the small volume of saliva present in the oral cavity, particularly when administration is via the sublingual cavity where saliva volume is limited; (b) oral transmucosal permeability, which requires that the active agent achieve rapid dissolution as a prerequisite for efficient absorption across the mucosal epithelium; and (c) compound stability, wherein certain active ingredients may be sensitive to degradation in oral transmucosal formulations, which could reduce the effective dose of active ingredient over time. The compositions described herein are formulated to address these challenges through appropriate selection of excipients, dosage forms, and manufacturing processes.
[0079] In some embodiments, the composition is formulated as an orally disintegrating dosage form that achieves the pharmacokinetic and pharmacodynamic parameters described herein when administered according to the method of the invention, i.e., by placing under or over the tongue and maintaining in contact with oral mucosal surfaces. The orally disintegrating dosage form may be an orally disintegrating tablet (ODT) or an orally disintegrating film (ODF), as described in further detail below.
[0080] Non-limiting examples of dissolvable film delivery systems include those disclosed in U.S. Pat. No. 4,136,145, U.S. Pat. No. 4,849,246, U.S. Pat. No. 5,629,003, U.S. Pat. No.5,948,430, U.S. Pat. No. 9,108,340, U.S. Pat. No. 8,906,277, U.S. Pat. No. 8,900,498, U.S. Pat. No. 8,900,497, U.S. Pat. No. 8,652,378, U.S. Pat. No. 8,603,514, U.S. Pat. No. 9,427,412, and U.S. Pat. No. 8,414,922, each of which is hereby incorporated by reference in their entirety. Other transmucosal systems are disclosed in U.S. Pat. No. 5,763,476 (sublingual and buccal solutions and solids), U.S. Pat. No. 9,216,175, U.S. Pat. No. 8,835,459, and U.S. Pat. No.6,552,024, each of which is hereby incorporated by reference in their entirety.
[0081] Some film delivery systems for use on mucosal surfaces may be adapted from disclosures in e.g., disclosure related to water-insoluble systems that may be in the form of laminated, extruded or composite films, are described in U.S. Pat. Nos. 4,517,173; 4,572,832; 4,713,243; 4,900,554; and 5,137,729, which are incorporated herein by reference in their entirety.
[0082] In some embodiments, the composition is in the form of an orally disintegrating tablet (ODT), which is a solid dosage form that dissolves or disintegrates rapidly in the mouth upon contact with saliva, without the need for water and without chewing. Orally disintegrating tablets disintegrate within seconds to minutes upon contact with saliva, substantially faster than conventional solid oral dosage forms intended to be swallowed intact. This rapid disintegration enables rapid release of the calcium channel blocker at the mucosal surface, facilitating transmucosal absorption. In some embodiments, the orally disintegrating tablets exhibit disintegration times of less than 60 seconds, less than 45 seconds, less than 30 seconds, or less than 15 seconds when tested according to standard pharmacopeial methods.
[0083] In some embodiments, the orally disintegrating tablet can include the active ingredient, at least one disintegrant, and at least one diluent. In addition, the orally disintegrating tablet may comprise a lubricant, an anti-caking agent, or a combination thereof.
[0084] For example, a suitable disintegrant may be one or more from methylcellulose, alginic acid, carboxymethylcellulose calcium, guar gum, carboxymethylcellulose sodium, polacrilinpotassium, croscarmellose sodium, poloxamer, crospovidone (cross-linked, water-insoluble polymer of polyvinylpyrrolidone (PVP)), sodium starch glycolate, and sodium alginate or combinations thereof. For example, the disintegrant can be crospovidone which may be present in the range of from about 0.025 wt.% to about 10 wt.%, including any ranges or values therein. For example, the disintegrant can be sodium starch glycolate which may be present in the range of from about 0.025 wt.% to about 10 wt.%, including any ranges or values therein. For example, the disintegrant can be croscarmellose sodium which may be present in the range of from about 0.025 wt.% to about 10 wt.%, including any ranges or values therein. Sodium starch glycolate, crospovidone, and croscarmellose sodium have good hydration capacity and flow properties. Further, they present the tendency to absorb water rapidly, so they swell in a significant amount, resulting in rapid and uniform disintegration.
[0085] For example, a suitable diluent may be one or more from dextrates, microcrystalline cellulose, dextrose, fructose, Sorbitol, pregelatinized starch, starch, xylitol, sucrose, maltodextrin, maltose, mannitol or combinations thereof. For example, the diluent may be microcrystalline cellulose which may be present in the range of from about 5 wt.% to about 40 wt.%, including any ranges or values therein. For example, the diluent may be mannitol present in the range of from about 40 wt.% to about 80 wt.%, including any ranges or values therein. Mannitol as a filler can provide its physicochemical properties, such as non-hygroscopicity, chemical inertness, and advantageous tableting behavior, including compactability. Microcrystalline cellulose can promote the efficient dry blending of ingredients and provide excellent compression of tablets.
[0086] For example, a suitable lubricant may be one or more from boric acid, magnesium stearate, Sodium Stearyl fumarate, micronized polyoxy ethylene glycol, leucine, sodium benzoate, sodium acetate, sodium lauryl sulfate, stearic acid, sodium stearate, sodium oleate, calcium stearate, waxes or any combination thereof. For example, the lubricant may be magnesium stearate which may be present in the range of from about 0.05 wt.% to about 10 wt.%, including any ranges or values therein.
[0087] For example, a suitable anti-caking agent may be silicon dioxide, magnesium stearate, talc, calcium silicate, and starch. These ingredients assist in maintaining consistent flow properties and minimizing aggregation or clogging during tableting operations and / or when the ODT disintegrates. For example, the anti-caking agent may be silicon dioxide which may be present in the range of from about 0.1 wt.% to about 3.0 wt.%, including any ranges or values therein.
[0088] In some embodiments, the orally disintegrating tablets possess sufficiently high tablet hardness and low friability to maintain integrity during packaging (e.g., into bottles and / or blisters), storage, and transportation. In some embodiments, the orally disintegrating tablets also rapidly disintegrate on contact with saliva, forming a smooth, easy-to-swallow suspension with non-gritty mouthfeel, or disintegrate within the prescribed period when tested with USP Method <701 > for Disintegration Time, as required for orally disintegrating tablets per the U.S. Food and Drug Administration (FDA) Guidance to Industry.
[0089] In some embodiments, the orally disintegrating tablet may be prepared via direct compression or freeze-drying (lyophilization). Direct compression involves blending the active ingredient with excipients and compressing the mixture into tablets without prior granulation, which can produce tablets with rapid disintegration characteristics. Lyophilization involves freezing an aqueous solution or suspension containing the active ingredient and excipients, followed by sublimation of the ice under vacuum to produce a porous tablet structure that disintegrates very rapidly upon contact with saliva. Both methods can produce tablets meeting the requirements under USP Method <701 > for Disintegration Time. The manufacturing method is selected based on the desired disintegration profile, tablet hardness requirements, and stability characteristics. Non-limiting examples of orally disintegrating tablets and methods of manufacturing same are disclosed in U.S. Pat. No. 4,134,943, U.S. Pat. Nos. 5,039,540, U.S. Pat. Nos. 5,079,018, U.S. Pat. No. 5,720,974, U.S. Pat. No. 5,178,878, U.S. Pat. No. 6,155,423, U.S. Pat. No. 6,311,462, U.S. Pat. No. 6,024,981, U.S. Pat. No. 6,200,604, U.S. Pat. No.5,464,632, U.S. Pat. No. 5,466,464, U.S. Pat. No. 5,576,014, U.S. Pat. No. 6,316,026, US 20030215500, US 20040122106, and US20050232988, each of which is hereby incorporated by reference in their entirety.
[0090] In some embodiments, the composition exhibits an in vitro dissolution profile wherein at least 70% of the active ingredient is released within 5 minutes when tested according to standard pharmacopeial methods. This rapid in vitro dissolution correlates with the rapid in vivo transmucosal absorption demonstrated in the Examples below. The rapid dissolution is achieved through the selection of appropriate disintegrants (such as crospovidone, croscarmellose sodium, or sodium starch glycolate), diluents (such as mannitol or microcrystalline cellulose), and manufacturing methods (such as direct compression or lyophilization).
[0091] Without being bound by any particular theory, the rapid in vitro dissolution performance of the compositions described herein (e.g., at least 70% release within 5 minutes) is believed to be a prerequisite for the rapid in vivo transmucosal absorption observed in the Examples. When the active ingredient is released rapidly from the dosage form upon contact with saliva at theoral mucosal surface, it becomes available for direct absorption across the mucosa into the systemic circulation. The animal pharmacokinetic studies described in Examples 3 and 4 demonstrate that this rapid release translates to a Tmax of approximately 5 minutes with peak plasma concentrations at the first sampling timepoint, while the human pharmacodynamic study of Example 6 demonstrates that the rapid systemic delivery produces measurable PR interval prolongation (an objective marker of AV-node calcium channel blockade) within 2 minutes and measurable heart rate effects within 2 to 5 minutes of sublingual administration. This in vitro-in vivo correlation confirms that the specifically formulated rapid-dissolving compositions, when administered by the transmucosal method described herein, achieve onset of pharmacodynamic effect on a timescale compatible with treatment of acute episode of cardiac arrhythmias.
[0092] In addition to orally disintegrating tablets, the compositions of the present disclosure may alternatively be formulated as orally disintegrating films, as described below.
[0093] In some embodiments, the composition is in the form of an orally disintegrating film (ODF), which is a thin, flexible film that dissolves or disintegrates rapidly in the mouth upon contact with saliva, without the need for water and without chewing. Orally disintegrating films disintegrate within seconds to minutes upon contact with saliva, typically faster than orally disintegrating tablets due to their thin profile and large surface area relative to mass. This rapid disintegration enables rapid release of the calcium channel blocker at the mucosal surface, facilitating transmucosal absorption. In some embodiments, the orally disintegrating films exhibit disintegration times of less than 60 seconds, less than 45 seconds, less than 30 seconds, or less than 15 seconds when tested according to standard pharmacopeial methods.
[0094] In some embodiments, the orally disintegrating film can include the active ingredient, at least one film-forming polymer, and at least one plasticizer. In addition, the orally disintegrating film may comprise a surfactant, a sweetener, a flavoring agent, or a combination thereof.
[0095] For example, a suitable film-forming polymer may be one or more from hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), pullulan, maltodextrin, carboxymethylcellulose sodium, methylcellulose, polyethylene oxide, sodium alginate, or combinations thereof. For example, the film-forming polymer can be hydroxypropyl methylcellulose which may be present in the range of from about 20 wt.% to about 60 wt.%, including any ranges or values therein. For example, the film-forming polymer can be pullulan which may be present in the range of from about 30 wt.% to about 70 wt.%, including any ranges or values therein. Hydroxypropyl methylcelluloseand pullulan have good film-forming properties, rapid dissolution characteristics, and provide a smooth mouthfeel upon disintegration.
[0096] For example, a suitable plasticizer may be one or more from glycerol, propylene glycol, polyethylene glycol, triacetin, triethyl citrate, sorbitol, or combinations thereof. For example, the plasticizer may be glycerol which may be present in the range of from about 5 wt.% to about 25 wt.%, including any ranges or values therein. For example, the plasticizer may be polyethylene glycol present in the range of from about 2 wt.% to about 15 wt.%, including any ranges or values therein. Plasticizers impart flexibility to the film, preventing brittleness and cracking during handling and storage, while maintaining rapid disintegration properties upon contact with saliva.
[0097] For example, a suitable surfactant may be one or more from polysorbate 80, sodium lauryl sulfate, lecithin, poloxamer, or combinations thereof. For example, the surfactant may be polysorbate 80 which may be present in the range of from about 0.1 wt.% to about 5 wt.%, including any ranges or values therein. Surfactants can enhance wetting and dissolution of the active ingredient upon contact with saliva, thereby facilitating rapid transmucosal absorption.
[0098] In some embodiments, the orally disintegrating films possess sufficient mechanical strength and flexibility to maintain integrity during packaging (e.g., into pouches, sachets, or blister packs), storage, and transportation. In some embodiments, the orally disintegrating films rapidly dissolve on contact with saliva, releasing the active ingredient for transmucosal absorption without the need for water or chewing.
[0099] In some embodiments, the orally disintegrating film may be prepared via solvent casting or hot-melt extrusion. Solvent casting involves dissolving or dispersing the active ingredient and excipients in a suitable solvent (typically water or a water-alcohol mixture), casting the solution onto a substrate, and drying to form a thin film. Hot-melt extrusion involves melting the film-forming polymer with the active ingredient and other excipients, extruding the molten mixture through a die, and cooling to form a film. Both methods can produce films with rapid disintegration characteristics suitable for transmucosal delivery. The manufacturing method is selected based on the desired dissolution profile, film thickness and uniformity requirements, and stability characteristics of the active ingredient.
[0100] In some embodiments, the composition of the present disclosure can comprise one or more permeation enhancers to increase the passage of active agents through the oral mucosa. Permeation enhancers or penetration enhancers or similar terms are used to describe materials that enhance permeation of a therapeutically or prophylact ically effective amount of active agentthrough the oral mucosa. Studies have suggested the feasibility of buccal delivery of even a rather large molecular weight pharmaceutical using a permeation enhancer (Aungst and Rogers, Int. J. Pharm. (1989) 53, pp. 227-235, which is incorporated herein by reference). The flux of active agent across the oral mucosa can be increased by changing either the resistance (i.e., the diffusion coefficient) or the driving force (i.e., the gradient for diffusion). Flux may be enhanced by the use of so-called permeation enhancers. Some permeation enhancers for use in the composition of the present disclosure include, but are not limited to, cell envelope disordering agents, solvents, steroidal detergents, bile salts, chelators, surfactants, nonsurfactants, fatty acids, and mixtures thereof. In some embodiments, the permeation enhancer may be a bile salt enhancer.
[0101] In some embodiments, the composition may further include one or more pharmaceutically acceptable excipients, carriers, or combinations thereof, formulated for transmucosal administration, particularly to sublingual surfaces.
[0102] In some embodiments, the composition is a single-dose pharmaceutical composition formulated for transmucosal administration to oral mucosa surfaces, such as sublingual administration. The pharmaceutical composition can be designed for self-administration by a subject with or without a delivery device.
[0103] In some embodiments, the subject self-administers the composition upon onset of symptoms of the acute episode of cardiac arrhythmia. The subject may recognize characteristic symptoms of an arrhythmic episode (such as palpitations, rapid heartbeat, chest discomfort, dizziness, or shortness of breath) and self-administerthe composition promptly upon symptom recognition. This self-administration upon symptom onset enables rapid therapeutic intervention without the delays associated with seeking professional medical care, thereby reducing the duration of the acute episode and the associated patient distress and clinical risk.
[0104] In some embodiments, the composition of the present disclosure includes the active ingredient in the form of free flowing rapidly dispersing microgranules. For example, such microgranules may include the active ingredient; a sugar alcohol, a saccharide or a mixture thereof; and a disintegrant.
[0105] In some embodiments, the composition of the present disclosure includes the active ingredient (such as verapamil and / or its active metabolite, norverapamil) in an amount of from about 100 ng to about 350 mg, or about 0.2 nanomoles to about 700 pmoles, including any ranges or values therein. For example, an amount of about 100-1000 ng, about 100-200 mg, about 100 ng-100 mg, about 100 ng-50 mg, about 1 mg-350 mg, about 1-100 mg, about 100-200 mg, about 200-350 mg, about 100-200 ng, about 200-300 ng, about 300-400 ng, about 400-500 ng, about 500-600 ng, about 600-700 ng, about 700-800 ng, about 800-900 ng, about 900-1000 ng, about 1-10 mg, about 10-20 mg, about 20-30 mg, about 30-35 mg, about 35-40 mg, about 40-45 mg, about 45-50 mg, about 50-55 mg, about 55-60 mg, about 60-65 mg, about 65-70 mg, about 70-75 mg, about 75-80 mg, about 80-85 mg, about 85-90 mg, about 90-95 mg, about 95-100 mg, about 100-150 mg, about 150-200 mg, about 200-250 mg, about 250-300 mg, about 300-350 mg, about 0.2-0.4 nanomoles, about 0.4-0.6 nanomoles, about 0.6-0.8 nanomoles, about 0.8-1 nanomoles, about 1-10 nanomoles, about 10-100 nanomoles, about 100-200 nanomoles, about 200-300 nanomoles, about 300-400 nanomoles, about 400-500 nanomoles, about 500-600 nanomoles, about 600-700 nanomoles, about 700-800 nanomoles, about 800-900 nanomoles, about 900-1000 nanomoles, about 1-10 pmoles, about 10-20 pmoles, about 20-30 pmoles, about 30-40 pmoles, about 40-50 pmoles, about 50-60 pmoles, about 60-70 pmoles, about 70-80 pmoles, about 80-90 pmoles, about 90-100 pmoles, about 100-150 pmoles, about 150-200 pmoles, about 200-250 pmoles, about 250-300 pmoles, about 300-350 pmoles, about 350-400 pmoles, about 400-450 pmoles, about 450-500 pmoles, about 500-600 pmoles, about 600-700 pmoles, about 100 ng, about 200 ng, about 300 ng, about 400 ng, about 500 ng, about 600 ng, about 700 ng, about 800 ng, about 900 ng, about 1 mg, about 10 mg, about 20 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, or about 350 mg.
[0106] In some embodiments, the composition of the present disclosure includes a pharmaceutically acceptable salt or free base of any suitable calcium channel blocker and / or active metabolite thereof. For example, the calcium channel blocker may be, but without being limited to, a compound (or a pharmaceutical salt, enantiomer, racemic mixture, active metabolite, or any combinations thereof) selected from the following table 1 :Table 1COB IUPAC nameVerapamil (2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2- propan-2-ylpentanenitrile1Gallopamil 5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5- trimethoxyphenyl)pentanenitrileDevapamil 2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-((m- methoxyphenethyl)methylamino)valeronitrileAmlodipine (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6- methyl-1,4-dihydropyridine-3,5-dicarboxylateDiltiazem c / s-(+)-[2-(2-Dimethylaminoethyl)-5-(4-methoxyphenyl)-3-oxo-6-thia-2-azabicyclo[5.4.0]undeca-7,9,11-trien-4-yl]ethanoateNifedipine dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5- dicarboxylateNimodipine 3-0-(2-methoxyethyl) 5-0-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1 ,4- dihydropyridine-3,5-dicarboxylateIsradipine 3-O-methyl 5-0-propan-2-yl 4-(2,1 ,3-benzoxadiazol-4-yl)-2,6-dimethyl-1 ,4- dihydropyridine-3,5-dicarboxylateLacidipine diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1- enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylateEtripamil methyl 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]- methylamino]ethyl]benzoateBenidipine 5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3- nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylateFelodipine 5-0-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4- dihydropyridine-3,5-dicarboxylateNicardipine 5-0-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3- nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylateLercanidipine 5-0-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
[0107] For example, a pharmaceutical salt of verapamil may be verapamil HCI (CAS Number: 152-11-4):HjCCH-3 NC - CH3H3CO. ...XOCH3.HC|H3CO" I J ~ II OCH3Molecular formula: C27H38N2O4 ■ HCIMolecular weight: 491.06 g / mol
[0108] For example, an active metabolite of verapamil can be norverapamil.
[0109] For example, an active metabolite of diltiazem can be N-desmethyl diltiazem.
[0110] In some embodiments, the composition of the present disclosure can include one or more ingredients from the following approved products in the United States: amlodipine (Norvasc™), amlodipine and atorvastatin (Caduet™), amlodipine and benazepril (Lotrel™), amlodipine and valsartan (Exforge™), amlodipine and telmisartan (Twynsta™), amlodipine and olmesartan (Azor™), amlodipine and olmesartan and hydroclorothiazide (Tribenzor™), amlodipine and aliskiren and hydroclorothiazide, amlodipine and perindopril (Prestalia™), clevidipine (Cleviprex™), diltiazem (Cardizem™), felodipine (Cardene™, Cardene SR), isradipine, nicardipine, nimodipine, nisoldipine (Sular™), and verapamil (Calan™).
[0111] In some embodiments, the composition of the present disclosure can have an in vitro dissolution profile suitable to achieve the herein described desired effect. In vitro dissolution profile can serve to determine the rate and extent of release of the active ingredient from the composition of the present disclosure. For example, the composition of the present disclosure can have an in vitro dissolution profile such that at least Cmax of the active ingredient is achieved at a period of from about 2 minutes to about 15 minutes, when dissolution is measured with the herein described dissolution test. For example, the composition can have an in vitro dissolution profile such that at least about 70 wt.% of the active ingredient is released at a time period of from about 10 seconds to 15 minutes, including any ranges or any values therein. For example, at least about 70 wt.% of the active ingredient can be released at a time period of about 10 seconds, about 30 seconds, about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes, about 15 minutes, between 10 seconds to 5 minutes, between 5-10 minutes, between 10-15 minutes, between 10 seconds to 1 minute, between 1-2 minutes, between 2-3 minutes, between 3-4 minutes, between 4-5 minutes, between 5-6 minutes, between 6-7 minutes, between 7-8 minutes, between 8-9 minutes, between 9-10 minutes, between 10-11 minutes, between 11-12 minutes, between 12-13 minutes, between 13-14 minutes, or between 14-15 minutes.
[0112] In some embodiments, after being released from the composition into the bloodstream via transmucosal absorption through the oral mucosa surfaces, the active ingredient can have an in vivo clearance profile suitable to achieve the herein described desired effect, e.g., without the active ingredient remaining in the individuals’ bloodstream for an excessive period. In some embodiments, the active ingredient can demonstrate an in vivo clearance profile wherein the blood concentration in an individual after about 1 hour is less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, or less than about 20% of the Cmax.
[0113] In some embodiments, the active ingredient in the form of a composition of the present disclosure can exhibit a pharmacokinetic profile suitable to achieve the herein described desired effect. The term pharmacokinetic profile (or “PK profile”) refers to the pattern of drug concentration in the body overtime following the administration of a drug. Pharmacokinetics is the study of how drugs are absorbed, distributed, metabolized, and excreted by the body (often abbreviated as ADME). For example, the composition can have a PK profile that is characterized by an average maximum active ingredient plasma concentration Cmax similar to that obtained with an intravenous (IV) administration. For example, Piao and Choi (Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res.2008 Apr;31(4):518-22) have reported the following values for intravenous administration of verapamil in rats:Table 2 Mean Plasma Pharmacokinetic Parameters of Verapamil in Rats after Oral (swallowed) and Intravenous AdministrationPK IV Verapamil Oral Oral Oral Parameters Verapamil Verapamil Verapamil (mg / kg) + Hesperidin (10 mg / kg) Cmax (ng / mL) - 58±14.0 115±28.9 119±30 Tmax (hr) - 0.25 0.5 0.5AUC 1838±159 253±58 433±108 498±124 (ng*hr / mL)Ti / 2(hr) 6.1±1.4 10.0±2.4 11.4±2.9 12.4±3.0 Kel (hr) 0.116±0.028 0.069±0.016 0.061±0.016 0.056±0.014 CL / F (mL / min) - 592±150 346±86.1 301±71.5F (%) _ - 4.6±1.3 7.9±2.0 9.0±2.4 AUC=area under the concentration-time curve; CL / F=apparent clearance; Cmax=maximal plasma concentration; F=bioavailability; Kei=elimination constant; Ti / 2=elimination half-life; Tmax=tirne of maximal plasma concentration.
[0114] In some embodiments, the active ingredient (such as verapamil and / or norverapamil) exhibits a pharmacokinetic (PK) profile characterized by an average CmaxOf at least 200 ng / mL after administration of a single dose. This Cmax is significantly higher than would be achieved with an equivalent oral swallowed dose due to avoidance of first-pass metabolism. For example, the composition may exhibit a Cmax of from about 200 ng / mL to about 1500 ng / mL after a single dose. For example, a Cmax of about 200 ng / mL, 300 ng / mL, 400 ng / mL, 500 ng / mL, 600 ng / mL, 700 ng / mL, 800 ng / mL, 900 ng / mL, 1000 ng / mL, 1100 ng / mL, 1200 ng / mL, about 200-300 ng / mL, about 300-400 ng / mL, about 400-500 ng / mL, about 500-600 ng / mL, about 600-700 ng / mL, about 700-800 ng / mL, about 800-900 ng / mL, about 900-1000 ng / mL, about 1000-1100 ng / mL, or about 1100-1200 ng / mL, after a single dose of about 30 mg. Critically for acute arrhythmia treatment, this Cmaxis achieved after a Tmax of less than or equal to about 15 minutes, including any range or values therein. For example, a Tmax of less than or equal to about 10 minutes. For example, a Tmax of less than or equal to about 5 minutes. As demonstrated in Example 4, the compositions achieved peak plasma concentration at the first sampling timepoint (5 minutes), indicating a Tmax of approximately 5 minutes or less. For example, the Tmax can be about 2-3 minutes, about 3-4 minutes, about 4-5 minutes, about 5-6 minutes, about 6-7 minutes, about 7-8 minutes, about 8-9 minutes, about 9-10 minutes, about 2-5 minutes, about 5-7 minutes, about 7-10 minutes, about 10-15 minutes, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8minutes, about 9 minutes, or about 10 minutes. This rapid Tmax directly addresses the unmet need for fast-acting acute arrhythmia treatment.
[0115] In some embodiments, the active ingredient (such as verapamil and / or norverapamil) may have an AUCcwof from about 100 ng*h / ml_ to about 1500 ng*h / ml_ after administration of a single dose to a subject. For example, an AUCo^of at least 100 ng*h / ml_ after administration of a single dose of about 30 mg to a subject. For example, an AUCo^of about 100 ng*h / ml_, about 200 ng*h / ml_, 300 ng*h / ml_, 400 ng*h / ml_, 500 ng*h / ml_, 600 ng*h / ml_, 700 ng*h / ml_, 800 ng*h / ml_, 900 ng*h / ml_, 1000 ng*h / ml_, 1100 ng*h / ml_, 1200 ng*h / ml_, about 100-200 ng*h / ml_ about 200-300 ng*h / ml_, about 300-400 ng*h / ml_, about 400-500 ng*h / ml_, about 500-600 ng*h / ml_, about 600-700 ng*h / ml_, about 700-800 ng*h / ml_, about 800-900 ng*h / ml_, about 900-1000 ng*h / ml_, about 1000-1100 ng*h / ml_, or about 1100-1200 ng*h / ml_, after administration of a single dose of about 30 mg to a subject, e.g., a mammalian subject such as a dog or a human being.
[0116] Without being bound by any particular theory, the transmucosal administration to oral mucosal surfaces of an active ingredient in the form of a composition of the present disclosure offers an innovative therapeutic approach that addresses the limitations of prior art treatments. This approach avoids the discomfort and inconvenience associated with intravenous or intranasal medication administration, thereby facilitating patient compliance and enabling selfadministration in non-clinical settings. The transmucosal administration offers the following technical advantages: (a) rapid alleviation of arrhythmia symptoms without significant off-target toxicity; (b) rapid infusion of the active ingredient into the bloodstream to promptly terminate cardiac arrhythmias, typically within minutes of administration; (c) quick metabolism and inactivation following the therapeutic effect, restoring normal heart rate without prolonged cardiovascular effects; and (d) patient self-administration outside clinical settings, reducing healthcare costs and patient burden.
[0117] In some embodiments, the present disclosure relates to a composition for patient selfadministration for treatment of an acute episode of cardiac arrhythmia outside a clinical setting. The composition comprises a therapeutically effective amount of verapamil or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, formulated as an orally disintegrating dosage form for placement under or over the tongue. The composition achieves a Tmax of less than or equal to about 10 minutes when maintained in contact with oral mucosal surfaces. The composition is advantageous for patient self-administration because it does not require water, medical supervision, or specialized equipment, can be stored at room temperature, and provides rapid therapeutic effect comparable to intravenous administration.
[0118] In some embodiments, the composition achieves a T max of less than or equal to about 10 minutes when administered by placing under or over the tongue and maintaining in contact with oral mucosal surfaces. In preferred embodiments, the Tmax is less than or equal to about 5 minutes. As demonstrated in the experimental results described herein, peak plasma concentration was observed at the first sampling timepoint (5 minutes post-administration), indicating the actual Tmax may be shorter.
[0119] In some embodiments, the active ingredient in the form of a composition of the present disclosure can be administered (used) in combination with a cardiovascular agent in an oral composition that is swallowed. For example, the administration (use) can be sequential or concomitant. For example, the cardiovascular agent can also be a calcium channel blocker, or can be any other suitable cardiovascular agent such as adenosine, beta blockers, digoxin, antiarrhythmic Class la (e.g., Procainamide, Quinidine, Disopyramide), antiarrhythmic Class Ic (e.g., Flecainide, Propafenone), antiarrhythmic Class III (e.g., Amiodarone, Sotalol, Dofetilide, Ibutilide), and the like.
[0120] In some embodiments, the composition of the present disclosure and the oral composition that is swallowed include the same calcium channel blocker, at the same or different dose.
[0121] In some embodiments, the composition of the present disclosure and the oral composition that is swallowed include a different calcium channel blocker, at the same or different dose.
[0122] In some embodiments, the composition formulated for transmucosal administration to oral mucosal surfaces and the oral composition that is swallowed are formulated into a bilayer tablet. The bilayer tablet configuration provides a dual-phase release profile that addresses both immediate and sustained treatment needs. For example, the bilayer tablet may comprise a first layer containing the composition formulated for transmucosal administration to oral mucosal surfaces, which facilitates a rapid increase in plasma concentration of the calcium channel blocker within a short timeframe (e.g., within 2 to 15 minutes). The bilayer tablet may further comprise a second layer (e.g., a core contained within the first layer or an adjacent layer) containing the oral composition that is swallowed, which provides a prolonged and stable plasma level over time through controlled or sustained release. By these means, the overall pharmacokinetic profile of the formulation may be modulated to provide both immediate symptom relief and prolonged therapeutic effect. For example, the bilayer tablet may comprise the composition formulated for transmucosal administration to oral mucosal surfaces forming an external layer, and the oral composition that is swallowed forming a core at least partiallyenclosed within the external layer. The pharmacokinetic advantage of this approach lies in the immediate release of the calcium channel blocker from the first layer allowing permeation through the oral mucosal surfaces, which causes a rapid rise in blood concentration for acute symptom control, followed by a controlled or sustained blood level due to delayed release from the core via gastrointestinal absorption.
[0123] It will be apparent from the present disclosure that using a bilayer tablet can provide several benefits to subjects suffering from cardiac arrhythmia, such as during acute episodes. Specifically, the active ingredient in the composition formulated fortransmucosal administration to oral mucosa surfaces addresses the immediate symptoms of an acute arrhythmic episode, while the subsequent controlled or sustained cardiovascular agent uptake helps prevent breakthrough episodes, thereby improving overall therapeutic effectiveness.
[0124] In a practical implementation, the herein described innovation may provide a therapeutic treatment method to address cardiac arrhythmia, particularly an acute arrhythmic episode.
[0125] In some embodiment implementation, the administration may include further oral administration (e.g., solid dosage form that is swallowed) of an effective amount of a second active ingredient in the form of a controlled or sustained release composition. For example, the active ingredient in the form of a composition of the present disclosure can form a first layer of a bilayer tablet whereas the second active ingredient in the form of a controlled or sustained release composition can form the core of the bilayer tablet.
[0126] In some embodiments, administration is through sublingual surfaces. In this administration, a dosage unit of the composition is placed in the sublingual cavity and the active ingredient is absorbed through the surrounding mucous membranes with minimal saliva response and minimal swallowing. This avoidance of gastrointestinal uptake allows for more rapid and consistent onset of action, more consistent plasma concentrations, and higher bioavailability.
[0127] In some embodiments, the subject places the composition in the sublingual cavity, allows the composition to dissolve or disintegrate without chewing, and consciously refrains from swallowing for about 10 minutes to maximize transmucosal absorption. During this period, any saliva containing dissolved active ingredient should be retained in the oral cavity rather than swallowed. After the period sufficient for transmucosal absorption has elapsed, any residual composition or saliva may be swallowed.
[0128] The following subsection provides additional detail on the pharmacology of verapamil, which is the calcium channel blocker exemplified in the compositions and examples described herein. While verapamil is described in detail, the skilled person will understand that the pharmacological principles apply, with appropriate modifications, to other calcium channel blockers suitable fortransmucosal administration.Pharmacology of Verapamil
[0129] Verapamil is an L-type calcium ion influx inhibitor (also known as a slow channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of arterial smooth muscle cells, as well as conductile and contractile myocardial cells. Without being bound by theory, verapamil does not directly modify calcium uptake, binding, or exchange by cardiac microsomes; its main locus of action is believed to be superficially-located membrane storage sites for calcium.
[0130] Electrical activity through the atrioventricular (AV) node depends, to a significant degree, upon calcium influx through the slow channel. By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner. This property accounts for the ability of verapamil to slow the ventricular rate in patients with chronic atrial flutter or atrial fibrillation, while normal sinus rhythm is usually not affected.
[0131] In some embodiments, verapamil may demonstrate tissue-specific effects. For example, in isolated rabbit heart studies, concentrations of verapamil that markedly affect sinoatrial (SA) nodal fibers or fibers in the upper and middle regions of the AV node have been shown to have very little effect on fibers in the lower AV node (NH region) and no effect on atrial action potentials or His bundle fibers.
[0132] Verapamil reduces afterload and myocardial contractility. Verapamil does not alter the normal atrial action potential or intraventricular conduction time, but in depressed atrial fibers it decreases amplitude, velocity of depolarization, and conduction velocity. Verapamil may shorten the antegrade effective refractory period of accessory bypass tracts. The depressant effects exerted by verapamil on AV nodal conduction may in part explain its effectiveness in treating supraventricular tachycardia. Overall, verapamil has a negative inotropic effect on isolated cardiac muscle.
[0133] In intact animals, the depressant effect of verapamil on cardiac output and stroke volume is dose-dependent. Although verapamil has local anaesthetic properties, in clinically relevant doses, it does not affect the rate of either the depolarization or the repolarization phase of the cardiac action potential. Verapamil does not have beta-blocking properties, although it antagonizes beta-adrenergic influences on the heart by a functional antagonism, due to its basic pharmacodynamic properties at the level of the conduction system and the myocardium.
[0134] Notably, verapamil is typically administered in its racemic form containing equal amounts of R-verapamil and S-verapamil. In isolated blood-perfused dog papillary muscle and isolated rabbit papillary muscle, the S-enantiomer has been reported to have 15 and 50 times the activity of the R-enantiomer in reducing myocardial contractility, respectively, and approximately twice the effect in reducing peripheral resistance. These stereochemical differences may be relevant to the compositions and methods described herein.
[0135] The skilled person will appreciate that while verapamil is exemplified herein, other calcium channel blockers with similar L-type calcium channel blocking activity, comparable physicochemical properties suitable for transmucosal absorption (e.g., water solubility, appropriate molecular weight, and lipophilicity), and appropriate cardiac pharmacodynamic effects may be used in the compositions and methods described herein. The selection of a particular calcium channel blocker is guided by the factors described above and the specific requirements for achieving the rapid transmucosal absorption and pharmacodynamic onset described herein.
[0136] The compositions described above may be provided in the form of kits or commercial packages, as described in the following subsection.Kits and Commercial Packages
[0137] In some embodiments, the composition described herein can be packaged in the form of a kit, a commercial package, and the like.
[0138] A “package” is generally understood as one or more components that are contained within conventional packaging material, such as a box, paper or plastic wrapping, or the like. The person skilled in the art would understand that a package may contain a single component, a plurality of the same component, one or more different components, or any combination of these without limitation. Where appropriate, a package may be defined more particularly as, for example, a commercial package or a pharmaceutical package. A “kit” is generally understood as a specific type of package that contains two or more components.
[0139] In some embodiments, the kit or commercial package may be partitioned to contain one or more containers, each of which may include one or more components of the composition. Suitable containers include bottles, vials, syringes, test tubes, and the like, made of various materials such as glass or plastic. Such kits optionally include identification statements, labels, or instructions for use. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, reflecting approval for human administration for treating a condition, disease, or disorder described herein.
[0140] In some embodiments, the kit or commercial package may include a label listing the contents and / or instructions for use, as well as a package insert with instructions for use. The label can be on or attached to the container, or mounted on top of the container. When present in a receptacle or carrier that also holds the container, the label accompanies the container as a package insert. The label may indicate that the content is intended for use in a particular therapeutic application, and may further indicate instructions regarding use in the methods disclosed herein.
[0141] In some embodiments, the kit or commercial package may include an instrument for administration (e.g., an applicator, empty syringe, or graduated cup), a separate formulating excipient, a separate activating agent, reagent, or buffer, an antiseptic wipe, a test strip, a separate product comprising a second active ingredient, or instructions defining the use.
[0142] The pharmaceutical compositions can be in unit dosage form. In such form, the composition can be divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations. The dosage form can be any form including, but not limited to, the forms described herein.
[0143] In some embodiments, a composition formulated for transmucosal administration and an oral composition that is swallowed are co-packaged as a kit or commercial package containing a plurality of dose units. This kit or commercial package can include a dose of the transmucosal composition alongside a plurality (e.g., at least two doses) of the oral composition. This packaging facilitates immediate management and short-term maintenance of the cardiovascular episode by providing patients with an immediate solution to terminate the episode (transmucosal composition) and maintain blood concentration of the active ingredient over subsequent days to prevent re-emergence of the cardiovascular episode.EXAMPLES
[0144] The following non-limiting examples demonstrate the preparation, characterization, and pharmacokinetic / pharmacodynamic properties of compositions according to the present disclosure. Example 1 describes formulation of orally disintegrating tablets; Example 2 provides dissolution and hardness testing data; Examples 3 and 4 present pharmacokinetic and pharmacodynamic animal studies comparing the transmucosal compositions to oral and intravenous reference products; Example 5 demonstrates combination therapy; and Example 6 presents human pharmacodynamic data demonstrating rapid onset of PR interval prolongation.Example 1 - Composition formulated for oral transmucosal administrations of a calcium channel blocker
[0145] In this example, illustrative examples of compositions formulated for oral transmucosal administration containing a calcium channel blocker were prepared. The non-limiting exemplified calcium channel blocker used here is verapamil HCI, however, the reader will readily understand that any other calcium channel blocker, pharmaceutically acceptable salt thereof, or active metabolite thereof, can be used instead, provided the active ingredient achieves suitable transmucosal absorption characteristics as described herein. Verapamil hydrochloride was selected for exemplification due to its established efficacy in treating cardiac arrhythmias, favorable water solubility for transmucosal formulation, and well-characterized pharmacology, but the invention is not limited thereto. The skilled person would understand that the same formulation principles and excipient selections can be applied to other calcium channel blockers listed in Table 1, including gallopamil, diltiazem, and pharmaceutically acceptable salts thereof.Table 3 - Prototype 1Ingredients wt.% Quantity per unit dose in mg Verapamil HCI 16.75 33.5 Crospovidone 5.00 10.0 Microcrystalline Cellulose (Avicel PH 101) 19.00 38.0Mannitol (Pearlitol 200 SD) 58.00 116.0 Magnesium Stearate 1.0 2.0Colloidal Silicon Dioxide (Aerosil 200 Pharma) 0.25 0.5Total 100 200Table 4 - Prototype 2Ingredients wt.% Quantity per unit dose in mg Verapamil HCI 16.75 33.5 Croscarmellose Sodium 2.50 5.0Sodium Starch Glycolate, (Type A) 2.50 5.0Microcrystalline Cellulose (Avicel PH 101) 13.0 26.0Mannitol (Pearlitol 200 SD) 64.0 128.0 Magnesium Stearate 1.0 2.0Colloidal Silicon Dioxide (Aerosil 200 Pharma) 0.25 0.5Total 100 200Table 5 - Prototype 3Qty per unit dose Ingredients wt.%in mg Verapamil HCI 16.75 33.5 Croscarmellose Sodium 5 10 Microcrystalline Cellulose (Avicel PH 101) 18.25 36.5Mannitol (Pearlitol 200 SD) 58 116Magnesium Stearate 1 2Colloidal SiliconDioxide (Aerosil 200 Pharma) 1 2Total 100 200Table 6 - Prototype 4Qty per unit dose Ingredients wt.%in mg Verapamil HCI 16.75 33.5 Croscarmellose Sodium 2.5 5Sodium Starch Glycolate, (Type A) 2.5 5 Microcrystalline Cellulose (Avicel PH101) 12.25 24.5Mannitol (Pearlitol 200 SD) 64 128Magnesium Stearate 1 2Colloidal Silicon Dioxide (Aerosil 200 Pharma) 1 2Total 100 200
[0146] The ingredients were formulated into an orally disintegrating 200 mg tablet using a compression method with a Natoli NP-RD10A.Example 2 - Dissolution test and hardness test
[0147] In this example, the dissolution performance and tablet hardness of the orally disintegrating tablet compositions prepared in Example 1 were evaluated. These tests demonstrate that the compositions achieve rapid in vitro dissolution (at least 70% release within 5 minutes) and sufficient mechanical integrity for pharmaceutical handling and packaging, confirming suitability for transmucosal drug delivery applications.
[0148] Dissolution test follows regulatory agency-recommended guidelines for immediate-release solid oral dosage forms. The dissolution method employed USP Apparatus II (paddles) at a rotation speed of 50 rpm. The dissolution medium was 0.01 N hydrochloric acid (HCI),prepared by pipetting 8.5 mL of hydrochloric acid and diluting to 10 L with purified water. A dissolution medium volume of 500 mL was used per vessel, maintained at a temperature of 37.0°C ± 0.5°C. Dissolution samples of 3 mL were collected manually at pull times of 0.5, 1 , 2, 5, 10, 15, and 30 minutes. No media replacement was performed between sampling time points. Samples were filtered through a 0.45 pm PVDF syringe filter prior to analysis.
[0149] Quantitative analysis of dissolved verapamil HCI was performed using an ultraperformance liquid chromatography (UPLC) system equipped with UV / PDA detection, a thermostatted column oven, and a binary or quaternary pump. The chromatographic column was a Waters Acquity HSS C18 column (1.7 pm particle size, 2.1 x 75 mm). An isocratic mobile phase system was employed consisting of Mobile Phase A (10 mM sodium acetate anhydrous in glacial acetic acid with 0.6% 2-aminoheptane) and Mobile Phase B (100% acetonitrile) at a ratio of 75:25 (A:B). Detection was performed at a wavelength of 278 nm, with PDA monitoring from 190 nm to 400 nm for identification purposes. The flow rate was 0.4 mL / min with an injection volume of 2 pL and a column temperature of 40°C ± 5°C. The run time was approximately 8 minutes or 2x the retention time of verapamil.
[0150] Working standard solutions were prepared at a concentration of approximately 0.05 mg / mL of verapamil HCI by accurately weighing approximately 10 mg of verapamil HCI reference standard into a 200 mL volumetric flask, adding approximately 70% of dissolution media, sonicating for 10 minutes or until fully dissolved, allowing the solution to cool to room temperature, then diluting to volume with dissolution media. For dissolution testing of the 20 mg tablets, individual tablets were weighed and each tablet was transferred into a separate dissolution vessel containing 500 mL of dissolution media, providing a target analytical concentration of approximately 0.04 mg / mL. For the 30 mg tablets, individual tablets were similarly weighed and transferred into dissolution vessels containing 500 mL of dissolution media, providing a target analytical concentration of approximately 0.06 mg / mL.
[0151] System suitability requirements included: the percent relative standard deviation (%RSD) of the verapamil HCI peak area from five working standard injections not more than (NMT) 2.0%; USP tailing factor of the verapamil HCI peak NMT 2.0; interference from diluent and placebo at the retention time of the verapamil HCI peak NMT 0.5% of the mean peak area of the five replicate standard injections; and the difference between weight-corrected peak responses of the verapamil HCI in two standard solutions NMT ± 2.0%.
[0152] Results for prototypes 1 and 2 are reported in the following tables:Table 7 - Dissolution test Prototype 1Amount Dissolved (%)Rep. 2 min 5 min 10 min 15 min 30 min 1 97 99 99 99 1002 95 99 99 100 993 81 101 101 101 101 4 71 99 99 100 1005 93 99 99 99 996 97 100 100 100 100 Mean 89 100 100 100 100 %RSD 11.9 0.8 0.8 0.7 0.8 Min 71 99 99 99 99Max 97 101 101 101 101Table 8 - Dissolution test Prototype 2Amount Dissolved (%)Rep. 2 min 5 min 10 min 15 min 30 min 1 95 99 98 98 972 100 101 100 101 100 3 90 103 103 103 101 4 0* 97 97 97 975 75 98 99 99 986 97 98 98 98 97 Mean 76 99 99 99 99 %RSD 50.3 2.2 1.9 2.1 1.9 Min 0 97 97 97 97Max 100 103 103 103 101‘artefact: this experiment should not be considered.
[0153] The resulting ODT tablets of 200 mg had an average hardness value in kiloponds of 5.06 + / - 2.3 (prototype 1) and 5.58 + / - 3.4 (prototype 2) [1 kiloponds (kp) or kilogram-force (kgf) is equal to exactly 9.80665 newtons],
[0154] The dissolution method was validated for specificity, linearity and range (covering approximately 10% to 300% of the target standard concentration, i.e., from 0.001 mg / mLto 0.2 mg / mL, with a correlation coefficient (r) requirement of > 0.998), accuracy (assessed at 50%, 100%, and 150% of the targeted analytical concentration, with percent recovery acceptancecriteria of 95% to 105%), and precision (repeatability, with %RSD of percent recovery NMT 5.0%). Solution stability of both standard and sample solutions was also evaluated. The validated analytical method confirmed that the dissolution results reported above are reliable and suitable for characterizing the rapid in vitro dissolution performance of the orally disintegrating tablet compositions described herein.Example 3 - PK / PD animal studies
[0155] A preliminary PK / PD study in dogs was conducted to obtain data on the PK profile, onset of action, and dose-dependency of the compositions of Example 1 compared to an oral verapamil reference product.
[0156] In this study, non-naive male Beagle dogs (n=3) were administered the verapamil oral reference product that is swallowed and the transmucosal verapamil compositions prototype 1 or 2, according to the study design in Table 9. A 3-day washout period was employed between treatment periods. On each PK sampling time point, heart rate was monitored for all groups. The reference oral verapamil product was administered in tablet form directly to the back of the mouth followed by 5 mL of water to facilitate swallowing. The compositions prototype 1 or 2 were administered as an oral dispersible tablet placed directly under the tongue. Before each administration, 5 mL of water was given in the mouth to facilitate dissolution.Table 9: Study Design of Dog PK StudyTreatment Test Article Day 1 Day 2 Day 3 Day 4 PK / PD Timepoints Period1 Verapamil 60 mg 60 mg 60 mg 120 0.25, 0.5, 1, 2, 4, 8 hr reference (AM) (AM) (AM) mg after AM dose only.60 mg 60 mg 60 mg (AM)(PM) (PM) (PM)2 Composition 33.5 mg 67 mg - - 0.25, 0.5, 1, 2 hr Prototype 1 (AM) (AM)or 2
[0157] A summary of the PK profile for compositions prototype 1 or 2 and for the verapamil reference product is provided in Table 10.Table 10: Summary of Pharmacokinetic Parameters for a Single Oral Dose of compositions prototype 1 or 2 and Verapamil Administered to Male DogsTest Article Dose Cmax T max AUCo-2h T-1 / 2 Kel (mg) (ng / mL) (hr) (ng hr / mL) (hr) (1 / hr) Verapamil Reference 60 215.0 0.8 264.0 2.04 0.34Verapamil Reference 120 482.3 1.0 668.5 2.37 0.29Prototype 1 33.5 354.5 0.25 203.0 0.84 0.83 Prototype 2 33.5 265.0 0.25 175.1 0.71 0.97Prototype 2 67 604.96 0.33 407.25 0.78 0.89 AUCo-2h=area under the curve from time zero until 2 hours post-dose; Cmax=maximal plasma concentration; Kei=elimination constant; Ti / 2=elimination half-life; Tmax=time of maximal plasma concentration.
[0158] Based on heart rate measurements, the transmucosal verapamil composition prototype 2 had a rapid onset of action with maximum effect at the first timepoint measured (i.e.15 min) post-dose for 33.5 mg and for 67 mg doses. A dose-dependent effect on heart rate was observed for the transmucosal verapamil composition prototype 2. These effects coincided with the Tmax of the rapid-uptake verapamil composition prototype 2, which occurred at first timepoint measured (i.e. 15 min) post-dose for the 33.5 mg dose and at 0.33 hours post-dose for the 67 mg dose. Comparatively, the Tmax for the verapamil reference product was 0.8 and 1.0 hours post-dose for the 60 and 120 mg doses, respectively.
[0159] Overall, the transmucosal verapamil compositions caused the verapamil to be very rapidly absorbed and rapidly cleared from systemic circulation, resulting in a higher Cmax value (Cmax=605 ng / mL for prototype 2 at 67 mg compared to 482 ng / mL for the verapamil oral reference product at 120 mg) and lower AUC0-2h value (AUC=407 ng hr / mL for prototype 2 at 67 mg compared to 668 ng hr / mL for the verapamil oral reference product at 120 mg). These improved results for the transmucosal verapamil compositions are significant as the verapamil being administered was at nearly half the dose compared to that of the verapamil oral reference product, demonstrating enhanced bioavailability through transmucosal absorption.
[0160] These results demonstrate the practical effectiveness of the herein described approach of transmucosal administration of a composition formulated for transmucosal administration to oral mucosa surfaces containing an active ingredient, for use in treating a cardiovascular condition, such as cardiac arrhythmia, in particular acute episode of cardiac arrhythmia.Example 4 - PK / PD animal studies (IV comparison)
[0161] A preliminary PK / PD study in dogs was conducted to obtain data on the PK profile, onset of action, and dose-dependency of compositions of Example 2 compared to a verapamil intravenous reference product.
[0162] In this study, non-naive male Beagle dogs (n=3) were administered the verapamil intravenous reference product and the composition formulated for transmucosal administration to oral mucosa surfaces prototype 2, according to the study design in Table 11. The referenceverapamil product was administered intravenously (IV). The composition prototype 2 was administered as an oral dispersible tablet (ODT) placed directly under the tongue. Before each composition prototype 2 administration, 5 mL of water was given in the mouth to facilitate dissolution.Table 11 : Study Design of Dog PK StudyTreatment Test Article Day 1 Day 4 Day 7 PK time PD time points Period points (min) (min)1 Verapamil 5 mg - - 5, 10, 15, 30, 0, 5, 10, 15, 20, reference bolus 60, 120 30, 45, 60, 90,1202 Composition - 33.5 mg 67 mg 5, 10, 15, 30, 0, 5, 10, 15, 20,Prototype 2 60, 120 30, 45, 60, 90,120
[0163] As shown in FIGS. 1 and 2, the overall effect of a transmucosal administration of a composition formulated for oral transmucosal administration containing verapamil on the heart rate is very similar to that one obtained with the intravenous administration of the reference product verapamil. Based on heart rate measurements, the composition formulated for oral transmucosal administration prototype 2 had a rapid onset of action with maximum effect at the first time point measured (i.e. 5 min), post-dose for 33.5 mg and for 67 mg doses. A dosedependent effect on heart rate was observed for the composition formulated for oral transmucosal administration prototype 2. These effects coincided with the Tmax of the composition formulated for oral transmucosal administration prototype 2, which occurred at the first time point measured (i.e. 5 min).
[0164] These results demonstrate the practical effectiveness of the herein described approach of transmucosal administration to oral mucosa surfaces of a composition formulated for oral transmucosal administration containing an active ingredient, for use in treating a cardiovascular condition, such as cardiac arrhythmia, in particular acute episode of cardiac arrhythmia.Example 5 Combination therapy: transmucosal administration of a composition formulated for oral transmucosal administration in combination with oral administration of a composition formulated for oral administration
[0165] A preliminary study was performed in dogs to test for the effect on heart rate with a transmucosal administration of a composition formulated for oral transmucosal administration in combination with oral administration of an oral composition (that is swallowed) with the same calcium channel blocker being contained in both compositions.
[0166] In this study, non-naive male Beagle dogs (n=3) were administered the composition formulated for oral transmucosal administration and / or an oral composition that is swallowed. On each PK sampling time point, heart rate was monitored for all groups. The oral composition was administered in tablet form directly to the back of the mouth followed by 5 mL of water to facilitate swallowing. The composition formulated for oral transmucosal administration prototype 2 was then administered as an oral dispersible tablet (ODT) placed directly under the tongue. Before each administration, 5 mL of water was given in the mouth to facilitate dissolution.
[0167] As shown in FIG. 3 the overall effect of a transmucosal administration to oral mucosa surfaces of a composition formulated for oral transmucosal administration containing verapamil on the heart rate has a rapid on-set and rapid clearance. When used in combination with verapamil in the form of an oral composition that is swallowed, the effect on the heart rate includes a rapid on-set followed by a sustained effect overtime.
[0168] These results demonstrate the practical effectiveness of the herein described combinatory therapy approach with a composition formulated for oral transmucosal administration to oral mucosa surfaces containing an active ingredient, and an oral composition that is swallowed, for treatment of a cardiovascular condition, such as cardiac arrhythmia, in particular acute episode of cardiac arrhythmia.Example 6 - Human Pharmacodynamic Study
[0169] A pharmacodynamic (PD) study was conducted to evaluate the cardiac electrophysiological effects of the transmucosal verapamil compositions described herein, using continuous electrocardiographic (ECG) monitoring. The study assessed both PR interval prolongation (a direct measure of atrioventricular (AV) node calcium channel blockade) and heart rate effects following sublingual administration.
[0170] In this study, a healthy human subject was administered the composition formulated for transmucosal administration to oral mucosal surfaces (prototype 2, verapamil HCI 33.5 mg) as an oral dispersible tablet placed directly under the tongue. The subject was instructed to allow slow disintegration with minimal swallowing. To evaluate the effect of sublingual retention time on pharmacodynamic response, the study systematically varied the duration of sublingual retention across multiple dosing sessions: 3 minutes, 4 minutes, 6 minutes, 10 minutes, and 15 minutes. ECG recordings were obtained at baseline (pre-dose) and at 2, 5, 10, 15, and 30 minutes post-dose. Heart rate was monitored continuously. The PR interval was measured from each ECG recording and expressed as a percentage of the pre-dose baseline value. The 10-minute retention time was evaluated at both the 1* dose (33.5 mg) and the 1.5* dose(approximately 50 mg, i.e., 1.5 tablets administered simultaneously). The 15-minute retention time was evaluated at the 1.5* dose. The 4-minute and 6-minute retention times were evaluated at the 1* dose.PR Interval Results
[0171] ECG recordings were obtained at baseline (pre-dose) and at 2, 5, 10, 15, and 30 minutes post-dose. Heart rate was monitored continuously. The PR interval was measured from each ECG recording and expressed as percentage change from the pre-dose baseline value. A separate dosing arm administered 33.5 mg at 1.5* the standard concentration (i.e., 1.5 tablets administered simultaneously) to assess dose-response.
[0172] The PR interval results, expressed as percentage of pre-dose baseline, are summarized in Table 12 below and depicted in FIG. 4 (which shows the 10-minute retention time arms). Table 12 presents the complete dataset across all retention times tested.Table 12: PR Interval (% of Baseline) as a Function of Sublingual Retention TimeMinutes Post3 min (1x) 4 min (1x) 6 min (1x) 10 min (1x) 10 min (1.5x) 15 min (1.5x) Dose0 (baseline) 100.0 100.0 100.0 100.0 100.0 100.0 2 98.5 109.6 109.5 106.0 109.0 120.2 5 81.3 110.4 108.0 108.5 107.5 117.0 10 79.9 106.7 106.6 112.3 108.6 115.4 15 98.5 104.4 108.0 109.1 111.2 118.6 30 106.0 106.7 104.4 108.4 110.0 115.4
[0173] FIG. 4 depicts the PR interval prolongation for the 10-minute retention time arms (1* and 1.5x doses). As shown in Table 12 and FIG. 4, at a retention time of 10 minutes, both the 1x and 1.5x doses produced robust, sustained PR prolongation. For the 1x dose, PR interval prolongation was first measurable within 2 minutes of administration, reaching approximately 6% above baseline at 2 minutes and a maximum of approximately 12% above baseline at 10 minutes, sustained at approximately 8-10% from 15 to 30 minutes. For the 1.5x dose, PR prolongation reached approximately 9% above baseline at 2 minutes and was sustained at approximately 8-11% above baseline throughout the 30-minute monitoring period.
[0174] At a retention time of 15 minutes (1.5x dose), PR interval prolongation was the most robust of all arms tested, reaching approximately 20% above baseline at 2 minutes post-dose and remaining sustained at approximately 15-19% above baseline throughout the 30-minute monitoring period. Comparison of the 15-minute and 10-minute arms at the same 1.5x dosedemonstrates that longer sublingual retention produces substantially greater and more sustained pharmacodynamic effect, consistent with greater total transmucosal absorption when the composition is maintained in contact with the mucosa for a longer period.
[0175] At retention times of 4 minutes and 6 minutes (both at the 1* dose), PR interval prolongation was present and measurable at all post-dose timepoints. Both arms showed comparable pharmacodynamic responses: PR interval reached approximately 8-10% above baseline at 2 and 5 minutes post-dose, and remained above baseline (approximately 4-8% above baseline) at the 10, 15, and 30-minute measurement timepoints. The magnitude and time course of the pharmacodynamic effect were similar between the 4-minute and 6-minute retention times, indicating that both retention periods achieved sufficient transmucosal absorption to produce measurable and sustained AV-node calcium channel blockade, though the effect was less robust and sustained than at the 10- and 15-minute retention times.
[0176] In marked contrast, at a retention time of 3 minutes (1 x dose), no significant sustained PR interval prolongation was observed. The PR interval remained at or below baseline at the 2-minute timepoint (approximately 98.5% of baseline), and then declined substantially below baseline at the 5- and 10-minute timepoints (approximately 81% and 80% of baseline, respectively), before returning to near baseline at 15 minutes (approximately 98.5%) and slightly above baseline at 30 minutes (approximately 106%). The absence of significant sustained PR interval prolongation, and the paradoxical PR interval shortening observed at 5 and 10 minutes, indicate that 3 minutes of sublingual retention was insufficient for meaningful transmucosal absorption of the active ingredient. This stands in sharp contrast to the 4-minute and 6-minute retention times, where measurable PR prolongation was present at all post-dose timepoints.
[0177] These results demonstrate a clear relationship between sublingual retention time and pharmacodynamic response. A sharp pharmacodynamic boundary was observed between 3 minutes and 4 minutes of sublingual retention: at 3 minutes, no significant sustained PR interval prolongation was achieved and paradoxical PR shortening was observed, whereas at 4 minutes and above, measurable and sustained PR prolongation was present at all post-dose measurement timepoints. Above this threshold, longer retention times produced progressively greater and more sustained PR interval prolongation, consistent with greater total transmucosal absorption of the active ingredient when the composition is maintained in contact with oral mucosal surfaces for longer periods. The 4-minute and 6-minute retention times produced comparable moderate pharmacodynamic effects, while the 10- and 15-minute retention times produced robust, sustained effects.
[0178] Without being bound by any particular theory, it is believed that the minimum period sufficient fortransmucosal absorption depends on the specific composition employed, including factors such as the dissolution rate of the dosage form, the physicochemical properties of the active ingredient (including molecular weight, lipophilicity, and aqueous solubility), the presence or absence of permeation enhancers or mucoadhesive excipients, and the surface area and geometry of the dosage form in contact with the mucosa. For the specific ODT compositions tested in this Example, a pharmacodynamic boundary was observed between 3 and 4 minutes of sublingual retention, with measurable pharmacodynamic effects present at retention times of 4 minutes and above. Compositions with faster dissolution rates, enhanced mucosal permeability characteristics, or dosage forms providing greater mucosal surface area (such as orally disintegrating films) may achieve sufficient transmucosal absorption in shorter retention periods than those observed for the specific ODT compositions tested in this Example. Conversely, compositions with slower dissolution profiles or active ingredients with lower mucosal permeability may require longer retention periods. The skilled person would understand that the minimum effective retention period can be determined for any particular composition by the methods described herein (i.e., monitoring PR interval prolongation or another suitable pharmacodynamic marker as a function of sublingual retention time). In some embodiments, transmucosal administration of the composition to oral mucosal surfaces of the subject produces a measurable prolongation of the PR interval relative to baseline within 10 minutes of administration. In preferred embodiments, the measurable prolongation of the PR interval is observed within 5 minutes of administration. In particularly preferred embodiments, the measurable prolongation of the PR interval is observed within 2 minutes of administration, as demonstrated in the experimental results described herein.Heart Rate Results
[0179] FIG. 5 reports the effect on heart rate, expressed as percentage change from baseline, following sublingual administration of the transmucosal verapamil composition prototype 2 (33.5 mg). Heart rate showed a rapid increase from baseline, reaching approximately 5% above baseline at 2 minutes post-dose, and 9% above baseline at 5 minutes post-dose. The heart rate remained elevated at approximately 8-10% above baseline throughout the 30-minute monitoring period.
[0180] In some embodiments, the transmucosal administration produces a measurable increase in heart rate relative to baseline within 5 minutes of administration. In some embodiments, the increase in heart rate is at least 5% above baseline within 5 minutes, or at least 8% above baseline within 5 minutes, or at least 10% above baseline within 5 minutes. Thisheart rate increase reflects the cardiovascular pharmacodynamic response to rapidly absorbed verapamil and demonstrates that therapeutically relevant plasma concentrations are achieved within minutes of sublingual administration.
[0181] The rapid onset of heart rate effect (within 2 minutes) is consistent with the pharmacokinetic profile of the transmucosal compositions, which achieve peak plasma concentrations at the first timepoint measurement (approximately 5 minutes post-dose, as shown in FIG. 1 and Table 10). The heart rate effect demonstrates that the compositions achieve systemic delivery of verapamil at concentrations sufficient to produce measurable cardiovascular pharmacodynamic effects within minutes of sublingual administration.PK / PD Correlation
[0182] As shown in FIG. 1, the plasma concentration of verapamil following transmucosal administration of the composition prototype 2 at 67 mg reached approximately 1150-1200 ng / mL at 5 minutes post-dose, followed by rapid decline to approximately 500-550 ng / mL at 10 minutes and approximately 280 ng / mL at 30 minutes. At the 33.5 mg dose, plasma concentration reached approximately 550-600 ng / mL at 5 minutes post-dose. In comparison, the intravenous reference product (5 mg bolus) reached a plasma concentration of approximately 175-200 ng / mL at 5 minutes post-dose. Notably, the transmucosal compositions achieved substantially higher plasma concentrations than the IV reference despite the non-invasive route, reflecting the rapid and efficient transmucosal absorption of verapamil from the specifically formulated compositions.
[0183] The temporal correlation between the rapid rise in plasma verapamil concentration (Tmax at approximately 5 minutes), the onset of PR interval prolongation (measurable at 2 minutes, peaking at 10 minutes), and the heart rate effect (measurable at 2 minutes) demonstrates a direct pharmacokinetic-pharmacodynamic relationship. This rapid PK / PD correlation confirms that the compositions achieve therapeutically relevant concentrations of verapamil at the AV node within minutes of sublingual administration, consistent with the rapid transmucosal absorption bypassing first-pass hepatic metabolism.
[0184] These results are in marked contrast to prior art sublingual verapamil formulations. As noted above, sublingual administration of a crushed verapamil 40 mg tablet (Securon) has been reported to produce a Tmax of approximately one hour, with the greater increase in PR interval occurring at approximately 30 to 90 minutes post-administration, which is a time frame too slow for effective acute arrhythmia management. The compositions of the present disclosure achieve measurable PR interval prolongation within 2 minutes and peak PR prolongation atapproximately 10 minutes, representing a significant improvement in onset of AV-node pharmacodynamic activity compared to crushed conventional verapamil tablets administered sublingually.
[0185] These pharmacodynamic results further support the utility of the compositions described herein for the treatment of an acute episode of cardiac arrhythmias, particularly paroxysmal supraventricular tachycardia (PSVT), where rapid AV-node blockade (as evidenced by PR interval prolongation) is the primary mechanism for terminating the re-entrant circuit responsible for the arrhythmia.Example 7 - Human Pharmacokinetic Study: Metabolite-to-Parent Ratio as a Biomarker for Transmucosal Absorption
[0186] A pharmacokinetic (PK) study was conducted in healthy human subjects (n=10 per part) to evaluate plasma concentrations of verapamil and its primary metabolite, norverapamil, following administration of a verapamil ODT composition at multiple dose levels compared to intravenous verapamil. Norverapamil is an active N-demethylated metabolite of verapamil that is formed predominantly by hepatic CYP3A4-mediated first-pass metabolism. Accordingly, the ratio of norverapamil to verapamil systemic exposure (measured as the ratio of AUC values) provides an objective pharmacokinetic biomarker for distinguishing transmucosal absorption (which bypasses first-pass hepatic metabolism) from gastrointestinal absorption (which subjects the active ingredient to extensive hepatic first-pass metabolism prior to reaching the systemic circulation).
[0187] In Part 1A, ten healthy subjects received, in a crossover design: (i) verapamil 10 mg administered intravenously (IV); (ii) verapamil 20 mg as an ODT; (iii) verapamil 30 mg as an ODT; and (iv) verapamil 40 mg as an ODT. Blood samples were collected at pre-dose, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 25 minutes, 50 minutes, 1.5 hours, 6 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose. Plasma concentrations of both verapamil and norverapamil were determined at each timepoint.
[0188] The norverapamil-to-verapamil AUC(inf) ratios were determined for each treatment arm. For intravenous administration (which delivers verapamil directly into the systemic circulation, bypassing hepatic first-pass metabolism), the metabolite-to-parent ratio was 0.26. In contrast, for the ODT arms, the metabolite-to-parent ratios were substantially higher: 1.04 (20 mg), 1.18 (30 mg), and 1.33 (40 mg). A separate cohort (Part 1B, n=10) confirmed these findings, with an IV 5 mg metabolite ratio of 0.32 compared to ODT 20 mg ratios of 1.24 (alone) and 1.19 (with co-administered oral care strips).Table 13 - Part 1A resultsVerapamil AUC(inf) Norverapamil AUC(inf) Metabolite-to-Parent Treatment(hr ng / mL) (hr ng / mL) RatioIV 10 mg 190.6 49.9 0.26ODT 20 mg 102.5 106.9 1.04ODT 30 mg 130.7 154.6 1.18ODT 40 mg 186.7 247.8 1.33Table 14 - Part 1B resultsVerapamil AUC(inf) Norverapamil AUC(inf) Metabolite-to-Parent Treatment(hr ng / mL) (hr ng / mL) RatioIV 5 mg 110.1 35.3 0.32ODT 20 mg 99.5 123.8 1.24ODT 20 mg106.5 126.6 1.19 w / Listerine
[0189] These metabolite-to-parent ratios demonstrate that, in this study, the majority of verapamil absorbed from the ODT formulations underwent hepatic first-pass metabolism prior to reaching the systemic circulation, indicating that subjects inadvertently swallowed a substantial proportion of the active ingredient rather than maintaining the composition in contact with the oral mucosal surfaces for the period sufficient fortransmucosal absorption as described herein. When verapamil is absorbed transmucosally (bypassing the liver), the expected metabolite-to-parent ratio would approach that observed following intravenous administration (approximately 0.26 to 0.32), because norverapamil formation occurs only via slower systemic hepatic metabolism rather than first-pass extraction. The substantially elevated ratios observed (1.04 to 1.33) are characteristic of conventional oral absorption with extensive first-pass metabolism, consistent with the known oral bioavailability of verapamil of approximately 20-35%.
[0190] Dose-proportionality analysis demonstrated that verapamil AUC(inf) increased proportionally with dose across the 20 mg to 40 mg range (power model exponent for AUC(inf) = 1.01, 95% Cl: 0.29-1.73, p = 0.0077), confirming linear pharmacokinetics within this dose range.
[0191] These results underscore the criticality of the method of administration described herein, specifically the requirement that the subject maintain the composition in contact with oralmucosal surfaces for a period sufficient for transmucosal absorption and refrain from swallowing during this period. When this method step is not properly followed (as evidenced by the elevated metabolite-to-parent ratios observed in this study), the pharmacokinetic profile reverts to that of conventional oral administration, with delayed Tmax and reduced bioavailability relative to true transmucosal absorption. Accordingly, the norverapamil-to-verapamil AUC ratio may serve as a pharmacokinetic biomarker for confirming transmucosal absorption: a ratio substantially below 1.0 (approaching the IV reference value of approximately 0.26 to 0.32) indicates predominantly transmucosal absorption, while a ratio at or above 1.0 indicates predominantly gastrointestinal absorption with first-pass hepatic metabolism.
[0192] These findings are consistent with the results of Example 6, in which a single subject who was specifically instructed to maintain the composition under the tongue with minimal swallowing for a retention time of 10 minutes achieved rapid onset of PR interval prolongation within 2 minutes of administration. Together, Examples 6 and 7 demonstrate that when the transmucosal method of administration is properly followed, the compositions of the present disclosure achieve rapid pharmacodynamic onset; conversely, when subjects do not adequately maintain mucosal contact (resulting in predominantly gastrointestinal absorption as confirmed by elevated metabolite-to-parent ratios), the rapid onset pharmacokinetic and pharmacodynamic advantages of the transmucosal approach are not realized.Pharmacokinetic Modeling Analysis
[0193] To further characterize the relative contributions of transmucosal absorption and gastrointestinal absorption in the study described above, a physiologically-based pharmacokinetic (PBPK) modeling analysis was performed. The model incorporated enantiomer-specific ADME parameters for both verapamil and norverapamil and was calibrated against intravenous reference data. Simulations were performed assuming varying fractions of the ODT dose swallowed (75%, 80%, 85%, and 90%, with the remainder absorbed through the oral mucosa), and the predicted verapamil and norverapamil plasma exposures were compared to the observed clinical data.
[0194] The modeling analysis estimated that approximately 20-25% of the 20 mg ODT dose, and approximately 20% of the 30 mg and 40 mg ODT doses, were absorbed through the oral mucosa, with the remainder being swallowed and absorbed via the gastrointestinal tract with associated first-pass hepatic metabolism. These estimates are consistent with the elevated metabolite-to-parent ratios reported above, which independently indicated that the majority of the absorbed verapamil underwent first-pass metabolism. The model further estimated an overall bioavailability of approximately 32% for the ODT compositions in this study, which isnotably greater than the approximately 14% bioavailability reported for conventional oral verapamil administration (i.e., tablets that are swallowed). This increased bioavailability, despite the substantial fraction of dose that was inadvertently swallowed, confirms that the transmucosal absorption fraction (approximately 20-25% of the dose) contributed meaningfully to systemic exposure by bypassing first-pass hepatic metabolism.
[0195] These modeling results provide further quantitative support for the conclusion that the method of administration described herein (specifically, maintaining the composition in contact with oral mucosal surfaces and refraining from swallowing) is critical to maximizing the proportion of the dose that is absorbed transmucosally. When this proportion is maximized (i.e., when swallowing is minimized), the expected bioavailability and rate of absorption would be substantially greater than observed in the present study, consistent with the rapid pharmacokinetic and pharmacodynamic results demonstrated in the animal studies of Examples 3 and 4 (where the method of sublingual placement was controlled by the experimenters) and in the human pharmacodynamic study of Example 6 (where the single subject was specifically instructed to minimize swallowing).
[0196] The Examples described above, taken together, demonstrate the technical contribution of the present invention: compositions formulated as orally disintegrating dosage forms that, when administered transmucosally according to the method described herein, achieve rapid onset of pharmacodynamic effect (PR interval prolongation within 2 minutes) suitable for treatment of an acute episode of cardiac arrhythmias outside a clinical setting.INDUSTRIAL APPLICABILITY
[0197] The compositions described herein can be manufactured using established pharmaceutical processes, including for example direct compression and lyophilization for orally disintegrating tablets. The compositions utilize commercially available, pharmaceutically acceptable excipients. The compositions and methods provide a practical solution for treatment of an acute episode of cardiac arrhythmias, enabling patient self-administration outside hospital settings. The kits and commercial packages can be produced, distributed, and stored using conventional pharmaceutical channels.
[0198] Other examples of implementations will become apparent to the reader in view of the teachings of the present description and as such, will not be further described here.
[0199] All references cited throughout the specification are hereby incorporated by reference in their entirety for all purposes.
[0200] Note that titles or subtitles may be used throughout the present disclosure for convenience of a reader, but in no way these should limit the scope of the disclosure. Moreover, certain theories may be proposed and disclosed herein; however, in no way they, whether they are right or wrong, should limit the scope of the disclosure so long as the disclosure is practiced according to the present disclosure without regard for any particular theory or scheme of action.
[0201] The use of “independently selected” in reference to a group of items indicates that selecting a specific item from the group is not influenced by any previous or subsequent selection from that group.
[0202] References to “some embodiments”, “one embodiment”, or “an embodiment” mean that the described element is included in at least one embodiment and may or may not be present in other embodiments. Described features may be combined in any suitable manner.
[0203] It will be understood by those of skill in the art that throughout the present specification, the term “a” used before a term encompasses embodiments containing one or more to what the term refers. It will also be understood by those of skill in the art that throughout the present specification, the term “comprising”, which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, un-recited elements or method steps.
[0204] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In the case of conflict, the present document, including definitions will control.
[0205] Unless otherwise noted, the expression “at least” or “at least one of” as used herein includes individually each of the recited objects after the expression and the various combinations of two or more of the recited objects unless otherwise understood from the context and use. The expression “and / or” in connection with two or more recited objects should be understood to have the same meaning unless otherwise understood from the context.
[0206] The use of the term “include,” “includes,” “including,” “have,” “has,” “having,” “contain,” “contains,” or “containing,” including grammatical equivalents thereof, should be understood generally as open-ended and non-limiting, for example, not excluding additional unrecited elements or steps, unless otherwise specifically stated or understood from the context.
[0207] Unless otherwise noted, the order of steps or order for performing certain actions is immaterial so long as the present disclosure remain operable. Moreover, two or more steps or actions may be conducted simultaneously.
[0208] Unless otherwise noted, the use of any and all examples, or exemplary language herein, for example, “such as” or “including,” is intended merely to illustrate better the present disclosure and does not pose a limitation on the scope of the disclosure. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the present disclosure.
[0209] The scope of the disclosure is defined by the appended claims, and modifications and variations apparent to those skilled in the art are encompassed therein.
[0210] The word “exemplary” is used herein to mean “serving as an example, instance, or illustration.” Any aspect described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other aspects. Unless specifically stated otherwise, the term “some” refers to one or more.
[0211] The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, and including the endpoints. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.
[0212] All structural and functional equivalents to the elements of the various aspects described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the claims.
[0213] Various modifications to the embodiments described herein will be readily apparent to those skilled in the art, and the general principles described herein can be applied to other embodiments without departing from the spirit or scope of the claims. Thus, it is understood that the scope of the claims fully encompasses other embodiments that may become obvious to those skilled in the art and that the scope of the claims are accordingly not limited.
[0214] Combinations, described herein, such as “at least one of A, B, or C,” “one or more of A, B, or C,” “at least one of A, B, and C,” “one or more of A, B, and C,” and “A, B, C, or any combination thereof’ include any combination of A, B, and / or C, and may include multiples of A, multiples of B, or multiples of C. Specifically, combinations such as “at least one of A, B, or C,” “one or more of A, B, or C,” “at least one of A, B, and C,” “one or more of A, B, and C,” and “A, B, C, or any combination thereof’ may be A only, B only, C only, A and B, A and C, B and C, or A and B and C, and any such combination may contain one or more members of its constituents A, B, and / or C. For example, a combination of A and B may comprise one A and multiple B’s, multiple A’s and one B, or multiple A’s and multiple B’s.
Claims
CLAIMS:
1. A composition comprising:a) a therapeutically effective amount of an active ingredient comprising a calcium channel blocker or a pharmaceutically acceptable salt, active metabolite, or combination thereof; andb) at least one pharmaceutically acceptable excipient, diluent, carrier, or combination thereofwherein the composition is formulated as an orally disintegrating dosage form for use in treatment of an acute episode of cardiac arrhythmia in a subject, wherein the treatment comprises placing the composition under or over the tongue of the subject and maintaining the composition in contact with oral mucosal surfaces for a period sufficient fortransmucosal absorption of the active ingredient directly into the systemic circulation through the oral mucosal surfaces,and wherein the transmucosal administration produces a measurable prolongation of the PR interval relative to baseline within 15 minutes of administration.
2. The composition for the use of claim 1 , wherein the composition comprises the active ingredient in an amount of from about 100 ng to about 350 mg.
3. The composition for the use of claim 1 or 2, wherein the calcium channel blocker is verapamil.
4. The composition for the use of any one of claims 1 to 3, wherein the composition is in the form of an orally disintegrating film or orally disintegrating tablet.
5. The composition for the use of any one of claims 1 to 4, wherein the cardiac arrhythmia is selected from the group consisting of paroxysmal supraventricular tachycardia (PSVT), supraventricular tachycardia (SVT), hypertrophic cardiomyopathy (HCM), inappropriate sinus tachycardia (1ST), atrial fibrillation (AFib), and postural orthostatic tachycardia syndrome (POTS).
6. The composition for the use of any one of claims 1 to 4, wherein the cardiac arrhythmia is paroxysmal supraventricular tachycardia (PSVT) with rapid ventricular response (RVR).
7. The composition for the use of any one of claims 1 to 6, wherein the measurable prolongation of the PR interval is observed within 10 minutes of administration.
8. The composition for the use of any one of claims 1 to 7, wherein the measurable prolongation of the PR interval is observed within 5 minutes of administration.
9. The composition for the use of any one of claims 1 to 8, wherein the measurable prolongation of the PR interval is observed within 2 minutes of administration.
10. The composition for the use of any one of claims 1 to 9, wherein the composition exhibits a pharmacokinetic profile characterized by a time to maximum plasma concentration (Tmax) of less than or equal to about 10 minutes.
11. The composition for the use of claim 10, wherein the Tmax is less than or equal to about 5 minutes.
12. The composition for the use of any one of claims 1 to 11, wherein the composition exhibits a maximum plasma concentration (Cmax) of at least 200 ng / mL after administration of a single dose.
13. The composition for the use of any one of claims 1 to 12, wherein the period sufficient fortransmucosal absorption is from about 4 minutes to about 15 minutes.
14. The composition for the use of claim 13, wherein the period sufficient for transmucosal absorption is at least 10 minutes.
15. The composition for the use of any one of claims 1 to 14, wherein the transmucosal administration produces a measurable increase in heart rate relative to baseline within 5 minutes of administration.
16. The composition for the use of any one of claims 1 to 15, wherein the measurable prolongation of the PR interval comprises an increase of at least 5% relative to baseline.
17. The composition for the use of any one of claims 1 to 16, wherein the composition exhibits a maximum plasma concentration (Cmax) of at least 500 ng / mL after administration of a single dose.
18. The composition for the use of any one of claims 1 to 17, wherein the measurable prolongation of the PR interval comprises an increase of at least 8% relative to baseline.
19. The composition for the use of any one of claims 1 to 18, wherein the measurable prolongation of the PR interval reaches a maximum at approximately 10 minutes postadministration.
20. The composition for the use of any one of claims 1 to 19, wherein the composition exhibits a rapid clearance profile characterized by a plasma concentration at 30 minutes post-administration that is less than about 30% of the maximum plasma concentration (Cmax).
21. A kit or commercial package for use in treatment of an acute episode of cardiac arrhythmia in a subject, comprising:a) a first dose of the composition as defined in any one of claims 1 to 20, wherein the active ingredient, is a first active ingredient; andb) one or more doses of an oral composition that is swallowed, the oral composition comprising a second active ingredient, wherein the first and the second ingredient are the same or differenttogether with instructions fortransmucosal administration of the first dose through oral mucosal surfaces.
22. A method for treatment of an acute episode of cardiac arrhythmia in a subject in need thereof, the method comprising:a) providing a composition comprising a therapeutically effective amount of an active ingredient comprising a calcium channel blocker or a pharmaceutically acceptable salt, active metabolite, or combination thereof; and at least one pharmaceutically acceptable excipient or carrier, wherein the composition is formulated as an orally disintegrating dosage form, andb) placing the composition under or over the tongue of the subject and maintaining the composition in contact with oral mucosal surfaces for a period sufficient for transmucosal absorption of the active ingredient directly into the systemic circulation through the oral mucosal surfaceswherein the transmucosal absorption produces a measurable prolongation of the PR interval relative to baseline within 15 minutes of administration.
23. The method of claim 22, wherein the cardiac arrhythmia is selected from the group consisting of paroxysmal supraventricular tachycardia (PSVT), supraventricular tachycardia (SVT), hypertrophic cardiomyopathy (HCM), inappropriate sinus tachycardia (1ST), atrial fibrillation (AFib), and postural orthostatic tachycardia syndrome (POTS).
24. The method of claim 22, wherein the cardiac arrhythmia is paroxysmal supraventricular tachycardia (PSVT) with rapid ventricular response (RVR).
25. The method of any one of claims 22 to 24, wherein the measurable prolongation of the PR interval is observed within 10 minutes of administration.
26. The method of any one of claims 22 to 25, wherein the measurable prolongation of the PR interval is observed within 5 minutes of administration.
27. The method of any one of claims 22 to 26, wherein the measurable prolongation of the PR interval is observed within 2 minutes of administration.
28. The method of any one of claims 22 to 27, wherein the period sufficient for transmucosal absorption is from about 4 minutes to about 15 minutes.
29. The method of claim 28, wherein the period sufficient for transmucosal absorption is about 10 minutes.
30. The method of any one of claims 22 to 29, wherein the composition exhibits a pharmacokinetic profile characterized by a time to maximum plasma concentration (Tmax) of less than or equal to about 5 minutes.
31. The method of any one of claims 22 to 30, wherein the transmucosal administration produces a measurable increase in heart rate relative to baseline within 5 minutes of administration.
32. The method of any one of claims 22 to 31, wherein during the period sufficient for transmucosal absorption, the subject refrains from swallowing to maximize transmucosal absorption and minimize gastrointestinal uptake.
33. The method of any one of claims 22 to 32, wherein the calcium channel blocker is verapamil.
34. The method of any one of claims 22 to 33, wherein the composition comprises the active ingredient in an amount of from about 100 ng to about 350 mg.
35. The method of any one of claims 22 to 34, wherein the composition is in the form of an orally disintegrating film or orally disintegrating tablet.
36. The method of any one of claims 22 to 35, further comprising sequential or concomitant administration of a cardiovascular agent that is swallowed.
37. The method of any one of claims 22 to 36, wherein the composition exhibits a maximum plasma concentration (Cmax) of at least 500 ng / mL after administration of a single dose.
38. The method of any one of claims 22 to 37, wherein the measurable prolongation of the PR interval comprises an increase of at least 8% relative to baseline.
39. The method of any one of claims 22 to 38, wherein the measurable prolongation of the PR interval reaches a maximum at approximately 10 minutes post-administration.
40. The method of any one of claims 22 to 39, wherein the composition exhibits a rapid clearance profile characterized by a plasma concentration at 30 minutes postadministration that is less than about 30% of the maximum plasma concentration (Cmax).
41. A composition for use in patient self-administration for treatment of an acute episode of cardiac arrhythmia outside a clinical setting, the composition comprising:a) a therapeutically effective amount of an active ingredient comprising verapamil or a pharmaceutically acceptable salt thereof; andb) at least one pharmaceutically acceptable excipient,wherein the composition is formulated as an orally disintegrating dosage form for placement under or over the tongue for transmucosal administration, and wherein the transmucosal administration produces a measurable prolongation of the PR interval relative to baseline within 15 minutes of administration.
42. A method for patient self-administration of treatment for an acute episode of cardiac arrhythmia outside a clinical setting, the method comprising:a) providing a composition comprising a therapeutically effective amount of an active ingredient comprising verapamil or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein the composition is formulated as an orally disintegrating dosage form;b) placing the composition under or over the tongue; andc) maintaining the composition in contact with oral mucosal surfaces for a period sufficient for transmucosal absorption of the active ingredient directly into the systemic circulation,wherein the transmucosal absorption produces a measurable prolongation of the PR interval relative to baseline within 15 minutes of administration.
43. The method of claim 42, wherein the measurable prolongation of the PR interval is observed within 10 minutes of administration.
44. The method of claim 42 or 43, wherein the measurable prolongation of the PR interval is observed within 5 minutes of administration.
45. The method of any one of claims 42 to 44, wherein the measurable prolongation of the PR interval is observed within 2 minutes of administration.
46. The method of any one of claims 42 to 45, wherein the period sufficient for transmucosal absorption is from about 4 minutes to about 15 minutes.
47. The method of any one of claims 42 to 46, wherein the composition achieves a time to maximum plasma concentration (Tmax) of less than or equal to about 5 minutes.
48. The method of any one of claims 42 to 47, wherein the composition achieves a maximum plasma concentration (Cmax) of at least 200 ng / mL after administration of a single dose.
49. The method of any one of claims 42 to 48, wherein the subject self-administers the composition upon onset of symptoms of the acute episode of cardiac arrhythmia.
50. The method of any one of claims 42 to 49, wherein during the period sufficient for transmucosal absorption, the subject refrains from swallowing to maximize transmucosal absorption and minimize gastrointestinal uptake.
51. The method of any one of claims 42 to 50, wherein the composition achieves a maximum plasma concentration (Cmax) of at least 500 ng / mL after administration of a single dose.
52. The method of any one of claims 42 to 51, wherein the measurable prolongation of the PR interval comprises an increase of at least 8% relative to baseline.
53. The method of any one of claims 42 to 52, wherein the measurable prolongation of the PR interval reaches a maximum at approximately 10 minutes post-administration.
54. The method of any one of claims 42 to 53, wherein the composition exhibits a rapid clearance profile characterized by a plasma concentration at 30 minutes postadministration that is less than about 30% of the maximum plasma concentration (Cmax).
55. A method for treatment of an acute episode of cardiac arrhythmia in a subject in need thereof, the method comprising:a) placing a composition comprising a therapeutically effective amount of an active ingredient comprising a calcium channel blocker or a pharmaceutically acceptable salt, active metabolite, or combination thereof, and at least one pharmaceutically acceptable excipient, under or over the tongue of the subject; andb) maintaining the composition in contact with oral mucosal surfaces for a period sufficient for transmucosal absorption of the active ingredient directly into the systemic circulation, wherein the transmucosal absorption produces a norverapamil-to-verapamil systemic exposure ratio of less than 1.0, as measured by the ratio of norverapamil area under the concentration-time curve (AUC) to verapamil AUC.
56. The method of claim 55, wherein the norverapamil-to-verapamil systemic exposure ratio is less than 0.75.
57. The method of claim 55, wherein the norverapamil-to-verapamil systemic exposure ratio is less than 0.5.
58. The method of claim 55, wherein the norverapamil-to-verapamil systemic exposure ratio is from about 0.2 to about 0.4.
59. A composition for use in treatment of an acute episode of cardiac arrhythmia in a subject, the composition comprising a therapeutically effective amount of an active ingredient comprising verapamil or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein the composition is formulated as an orally disintegrating dosage form for placement under or over the tongue, and wherein the composition, when maintained in contact with oral mucosal surfaces for transmucosal absorption, exhibits an absolute bioavailability of at least 25%.
60. The composition for the use of claim 59, wherein the absolute bioavailability is at least 30%.
61. The composition for the use of claim 59, wherein the absolute bioavailability is at least 40%.
62. The composition for the use of claim 59, wherein the absolute bioavailability is at least two-fold greaterthan the bioavailability of an equivalent dose of verapamil administered as a conventional oral swallowed tablet.
63. A composition for use in treatment of an acute episode of cardiac arrhythmia, the composition comprising verapamil or a pharmaceutically acceptable salt thereof in an amount of from about 20 mg to about 40 mg, and at least one pharmaceutically acceptable excipient, wherein the composition is formulated as an orally disintegrating dosage form, and wherein the composition exhibits dose-proportional pharmacokinetics across the dose range, as characterized by a power model exponent for area under the concentration-time curve (AUC) of from about 0.8 to about 1.
2.
64. A method for patient self-administration of treatment for an acute episode of cardiac arrhythmia outside a clinical setting, the method comprising:a) placing a composition comprising a therapeutically effective amount of verapamil or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, formulated as an orally disintegrating dosage form, under or over the tongue;b) maintaining the composition in contact with oral mucosal surfaces for a period sufficient for transmucosal absorption of the active ingredient directly into the systemic circulation; andc) refraining from swallowing during the period of transmucosal absorption, wherein the transmucosal absorption produces both (i) a measurable prolongation of the PR interval relative to baseline within 15 minutes of administration, and (ii) a norverapamil-to-verapamil systemic exposure ratio indicative of predominantly transmucosal absorption rather than gastrointestinal absorption.
65. The method of claim 64, wherein the norverapamil-to-verapamil systemic exposure ratio indicative of predominantly transmucosal absorption is a ratio of less than 1.0, as measured by the ratio of norverapamil AUC to verapamil AUC.
66. The method of any one of claims 42 to 65, wherein the period sufficient for transmucosal absorption is from about 4 minutes to about 15 minutes.
